A Phase 3, Open Label, Single Arm Study to Evaluate Efficacy, Safety and Tolerability of Aficamten in Adult Japanese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Researchers are looking for a better way to treat Japanese people who have symptomatic obstructive hypertrophic cardiomyopathy (symptomatic oHCM).
Obstructive hypertrophic cardiomyopathy (oHCM) is a type of heart disease where the heart muscles become thicker than normal due to over contraction. This thickening makes it harder than normal due to over contraction. This thickening makes it harder for the heart to pump blood out to the rest of the body. In symptomatic oHCM people with the condition experience symptoms like shortness of breath, chest pain, fainting, high blood pressure and irregular heartbeats.
The study treatment aficamten, also called BAY3723113, is under development to treat symptomatic oHCM. It aims to reduce the activity of cardiac myosin, a protein that helps heart muscles to contract, and thereby preventing over contraction and muscle thickening.
Although treatment options are available for symptomatic oHCM, there is still need for other treatment options that help target the root cause of the condition. In this study, researchers want to understand about the effects and long-term safety of aficamten in Japanese people with symptomatic oHCM.
The main purpose of the study is to learn how well aficamten works in Japanese with symptomatic oCHM.
For this, the researchers will check how participant's heart blood flow changes after 6 months of treatment. They do this by measuring the pressure needed for blood to leave the heart using a test called the left ventricular outflow tract (LVOT) gradient and a special breathing technique called Valsava maneuver.
Researchers will also look for:
* the number of participants who will have at least 1 level improvement on a scale doctors use to assess the effect of heart problems on daily activities after 3 and 6 months of treatment
* the change in the impact of heart problems on participant's daily lives based on their feedback on a questionnaire called Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS) after 3 and 6 months of treatment.
This study will have 2 treatment periods: main treatment period and long-term treatment period. During the main treatment period, participants will take aficamten tablets once daily by mouth for up to 6 months. After completing this period, the participants who can join the long-term treatment period will continue taking aficamten until the drug becomes commercially available in Japan or the study ends.
Each participant will be in the study as long as they benefit from the treatment.
Participants will visit the study site:
* once before the treatment starts
* 9 times with a gap of 2 to 4 weeks between the visits during treatment under the main treatment period, and in the long-term treatment period, participants will visit almost every 3 months until the treatment ends.
* then 2 more times with a gap of 1 month between the visits after the treatment ends.
During the study, the study doctors and their team will:
* check participant's health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram (ECG) and echocardiogram (ECHO)
* ask the participants questions about how they are feeling and what adverse events are they having
An adverse event is any medical problem that a participant has during a study. Study doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment. In addition, the participants will be asked to complete a questionnaire on quality of life at certain time points during the study.
If the participant benefits from the treatment, treatment with aficamten after the end of the study might be possible.

开始日期2025-06-30

申办/合作机构

Bayer AG

NCT06412666

/ Recruiting临床2/3期

A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy

The purpose of this study is to evaluate the efficacy, safety and PK of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

开始日期2024-05-29

申办/合作机构

Cytokinetics, Inc.

NCT06116968

/ Recruiting临床3期

An Open-Label Study of Aficamten for Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

This is an open-label extension study of China cohort in the phase 3 study (CY 6031) of aficamten for the treatment of obstructive HCM (oHCM) to collect long-term safety and tolerability data, including assessments of cardiac function and steady-state Pharmacokinetics (PK) during chronic dosing with aficamten.

开始日期2023-11-14

申办/合作机构-

100 项与艾非凯泰相关的临床结果

登录后查看更多信息

100 项与艾非凯泰相关的转化医学

登录后查看更多信息

100 项与艾非凯泰相关的专利（医药）

登录后查看更多信息

项与艾非凯泰相关的文献（医药）

2025-12-01·Journal of cardiovascular imaging

Cardiac myosin inhibitors in hypertrophic cardiomyopathy

Review

作者: Lim, Jaehyun ; Kim, Hyung-Kwan

Abstract:

Mavacamten, the first selective and reversible cardiac myosin inhibitor (CMI), has been introduced to the clinical arena for the treatment of obstructive hypertrophic cardiomyopathy (HCM). By reducing excessive actin-myosin cross-bridging, this agent decreases myocardial contractility and alleviates the dynamic left ventricular outflow tract (LVOT) obstruction in obstructive HCM. In the EXPLORER-HCM trial, mavacamten significantly improved exercise capacity, symptoms, and LVOT pressure gradients, while the VALOR-HCM trial proved it can obviate the need for septal reduction therapy in patients who were deemed to be candidates for septal reduction therapy. Notably, long-term data (MAVA-LTE study) has demonstrated sustained benefits up to 180 weeks, with < 10% experiencing transient reductions in left ventricular ejection fraction < 50% and only 1.3% of permanent discontinuation rate. Aficamten, a next-generation CMI with a shorter half-life, has also demonstrated comparable efficacy. Reverse remodeling following treatment was noted in both agents. In nonobstructive HCM, preliminary studies (MAVERICK-HCM trial and cohort 4 of REDWOOD-HCM trial) have reported improvements in cardiac serum biomarkers and symptoms. However, the preliminary results from phase 3 trials (ODYSSEY-HCM trial) revealed that primary endpoints were not met in nonobstructive HCM. Regarding safety, both were generally well tolerated. Although an LVEF reduction occurred in some patients, it was reversible with a dose reduction or a short-term drug cessation. These results emphasize careful dosing strategy with regular echocardiographic monitoring. Real-world data have also demonstrated consistent efficacy and safety across varying ethnic groups without new safety signals. CMI is a major advance in HCM management. However, future studies must provide data on hard clinical outcomes, such as heart failure hospitalization or death. Ongoing trials comparing CMI to traditional first-line therapies, such as β-blockers, will clarify their potential role as an initial therapeutic option.

2025-10-22·EUROPEAN HEART JOURNAL

Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial

Article

作者: Coats, Caroline J ; Nassif, Michael E ; Claggett, Brian L ; Veselka, Josef ; Wohltman, Amy ; Malik, Fady I ; Maron, Martin S ; Barriales-Villa, Roberto ; Gimeno, Juan Ramon ; Heitner, Stephen B ; Januzzi, James L ; Kupfer, Stuart ; Jacoby, Daniel L ; Spertus, John A ; Masri, Ahmad ; Hegde, Sheila M ; Kulac, Ian J ; Olivotto, Iacopo

Abstract:

Background and Aims:

Patients with obstructive hypertrophic cardiomyopathy (oHCM) treated with aficamten in SEQUOIA-HCM (NCT05186818) demonstrated marked improvement in symptoms and functional capacity. This analysis explores whether oHCM and mild symptoms patients experience similar clinical benefits with aficamten as patients with more advanced limitations.

Methods:

Patients in SEQUOIA-HCM (N = 282) were grouped at baseline according to symptom severity. Mild symptoms (n = 118) were defined as New York Heart Association (NYHA) class II and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) ≥ 80, and moderate to severe symptoms (n = 150) as NYHA class II/III/IV and KCCQ-CSS <80. Primary endpoint was change in peak oxygen uptake (pVO2) from baseline to Week 24; secondary endpoints included change in NYHA class, KCCQ-CSS, outflow tract gradients, and N-terminal pro-B-type natriuretic peptide (NT-proBNP).

Results:

In aficamten-treated patients, change at Week 24 was not different between moderate to severe (1.8 mL/kg/min; n = 71) and mild (1.6 mL/kg/min; n = 62) symptom groups (P = .8). Likewise, the change in secondary endpoints (NYHA class, resting or Valsalva gradients, and NT-proBNP) did not differ significantly between the two symptom groups. Both groups experienced statistically significant improvements in KCCQ-CSS, but the extent of improvement was greater in the advanced symptom group (P = .02 for interaction). Treatment-emergent serious adverse events were infrequent in both groups.

Conclusions:

Patients with oHCM and mild symptoms treated with aficamten achieved significant improvement across a range of clinically relevant outcomes and generally similar to patients with more advanced symptoms. Less severely symptomatic patients could be considered for aficamten treatment.

2025-10-07·CIRCULATION

Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial

Article

作者: Kulac, Ian J. ; Owens, Anjali T. ; Malik, Fady I. ; Wohltman, Amy ; Claggett, Brian L. ; Campain, Joseph ; Griskowitz, Catharine ; Kupfer, Stuart ; Prasad, Cheshta ; Moreno, Fabely ; Coats, Caroline J. ; Heitner, Stephen B. ; Newlands, Chloe ; Lee, Matthew M.Y. ; Malhotra, Rajeev ; Landsteiner, Isabela ; Minasian, Alexandra ; Giverts, Ilya ; Maron, Martin S. ; Jacoby, Daniel L. ; McGinnis, Shaina ; Lewis, Gregory D. ; Iskenderian, Nick ; Rupert, Lillian

BACKGROUND::

Post-exercise oxygen uptake recovery (VO 2 Rec) is slow in advanced heart failure. We sought to establish easily derived VO 2 Rec measures and evaluate their cardiospecificity and prognostic relevance in patients with dyspnea on exertion. We further sought to determine VO 2 Rec modifiability proportional to changes in cardiac function with disease-specific treatment of obstructive hypertrophic cardiomyopathy.

METHODS::

VO 2 Rec patterns were evaluated in relation to cardiac performance and the primary outcome of heart failure hospitalization or death in a referral cohort with dyspnea on exertion undergoing cardiopulmonary exercise testing with hemodynamic monitoring (MGH-ExS [Massachusetts General Hospital Exercise Study]). We then investigated longitudinal measures of VO 2 Rec in the pivotal phase 3 randomized controlled trial SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in Hypertrophic Cardiomyopathy) of aficamten versus placebo for 24 weeks in participants with symptomatic obstructive hypertrophic cardiomyopathy. For both cohorts, VO 2 Rec was uniformly measured as time for VO 2 to decline by >0%, 12.5% (VO 2 T 12.5% ), 25%, and 50% of peak VO 2 .

RESULTS::

Among 814 MGH-ExS patients (58±16 years of age, 58% women), those with a longer VO 2 T 12.5% (≥35 versus <35 seconds) demonstrated elevated exercise pulmonary capillary wedge pressure to cardiac output slope ( P <0.0001) with no difference in peripheral oxygen extraction ( P =0.11). For each 15-second increase in VO 2 T 12.5% , the hazard ratio for heart failure hospitalization and all-cause death was 1.54 (95% CI, 1.35–1.76; P <0.001). In SEQUOIA-HCM participants with cardiopulmonary exercise testing at baseline and week 24 (n=263, 59.1±2.9 years of age, 41% women), baseline VO 2 T 12.5% was 45±20 seconds and improved 8 seconds (95% CI, −12 to −5 seconds; P <0.001) with aficamten treatment compared with placebo at 24 weeks. Participants treated with aficamten versus placebo were more likely to improve VO 2 T 12.5% by ≥15 seconds (odds ratio [OR], 3.7 [95% CI, 1.9–6.9]; number needed to treat=4.8). Shortening of VO 2 T 12.5% correlated with reduced NT-proBNP (N-terminal pro-B-type natriuretic peptide), high-sensitivity cardiac troponin I, and left ventricular outflow tract gradient (all P <0.005).

CONCLUSIONS::

This study established VO 2 T 12.5% as a new measure that reflects cardiac performance during exercise and predicted heart failure event-free survival. Furthermore, VO 2 T 12.5% improved proportional to improvements in left ventricular outflow tract gradient and cardiac biomarkers in response to aficamten treatment, a cardiospecific therapy for obstructive hypertrophic cardiomyopathy. The simplicity and physiological relevance of VO 2 T 12.5% support its regular inclusion in cardiopulmonary exercise testing protocols evaluating cardiac function during exercise.

REGISTRATION::

URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05186818.

341

项与艾非凯泰相关的新闻（医药）

2025-10-28

·药事纵横

2025年收官季FDA值得关注的6项决定

转眼间，2025年已进入最后一个季度。美国FDA的审批日历也排得满满当当——未来三个月，将有超过30项新药申请等待裁决。这绝非一个平静的收尾，相反，它可能是今年生物医药领域最激动人心的时刻。其中，有六项关键决定备受瞩目，它们或将为难治性疾病带来突破，甚至开创全新的治疗模式。今天，我们就来盘点这六大可能撼动医药行业的重磅审批。 01 再生元：高剂量Eylea HD能否“双喜临门”？决定时间： 2025年第四季度（具体日期待定）核心看点：能否将高剂量Eylea（Eylea HD）的适应证扩展至视网膜静脉阻塞（RVO）后的黄斑水肿，并批准其每月一次的给药方案。这款药物原本在8月就有结果，但因第三方生产工厂的“生产质量问题”（据报告甚至涉及细菌和猫毛污染）而被推迟。尽管生产环节“掉链子”，再生元公司对获批依然信心十足。为了支持其在高剂量 Eylea 中的应用，再生元提交了 III 期 QUASAR 研究的数据，该研究表明，高剂量制剂在用于治疗 RVO 后黄斑水肿患者时，不劣于目前批准的标准剂量版本的 Eylea。两种制剂之间的不良事件相当。高剂量 Eylea 目前已被批准用于治疗湿性年龄相关性黄斑变性、糖尿病性黄斑水肿和糖尿病视网膜病变。临床价值：如果成功获批，将为RVO引发的视力损伤患者提供一个更强效、更便捷的治疗选择。 02 葛兰素史克：抗癌药Blenrep能否“卷土重来” 最终决定日： 2025年10月23日核心看点：曾被撤市的抗癌药Blenrep，能否作为多发性骨髓瘤的二线治疗药物重返市场。 Blenrep在2020年凭借加速通道获批，但因后续验证性临床试验未达到主要终点，于2022年底主动撤市。如今，葛兰素史克携两项成功的III期临床数据，试图让这款药物“王者归来”。 III 期 DREAMM-7 试验的数据显示，与使用强生 Darzalex 的类似方案相比，接受 Blenrep 联合硼替佐米和地塞米松治疗的患者死亡或疾病进展风险显着降低了 59%。另一项后期研究 DREAMM-8 的结果，宣称 Blenrep 的无进展生存期明显优于武田的 Velcade。葛兰素史克正在利用这两项研究来支持其对 Blenrep 的监管申请，但今年 7 月，FDA 的内部审查员在这两项试验中都标记了“高眼毒性和剂量调整率”。投票后不久，FDA 将 Blenrep 的审查延长了三个月。 03 百时美施贵宝：Breyanzi挑战首个治疗边缘区淋巴瘤的CAR-T疗法最终决定日： 2025年12月5日核心看点：其CAR-T疗法Breyanzi，有望成为首个用于边缘区淋巴瘤（MZL）的CAR-T细胞治疗。 BMS 提交了 II 期 TRANSCEND FL 研究的结果，这是一项单臂、开放标签试验，招募了 270 多名复发或难治性滤泡性淋巴瘤或 MZL 患者。6 月在 2025 年国际恶性淋巴瘤会议上公布的数据显示，MZL 患者的总体缓解率为 95.5%，其中 62.1% 的患者出现完全缓解。 TRANSCEND FL 的安全性与之前为 Breyanzi 确定的安全性一致。根据 BMS 的数据，细胞因子释放综合征和神经系统并发症的发生率“很低”，没有检测到 4 级或 5 级病例。如果它赢得 FDA 的批准，Breyanzi将成为第一个针对 MZL 的 CAR T 疗法。这也标志着 Breyanzi 第二次创下监管记录：2024 年 3 月，它成为第一个获得批准用于复发/难治性慢性淋巴细胞白血病和小淋巴细胞白血病的 CAR-T。 04 Arrowhead：plozasiran瞄准超罕见胆固醇疾病的RNAi疗法最终决定日： 2025年11月18日核心看点： RNAi（RNA干扰）疗法plozasiran能否获批用于治疗家族性乳糜微粒血症综合征（FCS）。 FCS 是一种极其罕见的遗传性疾病，每百万人中有 1 至 2 人受到影响，根据Arrowhead 的说法，表现为甘油三酯水平过高，通常达到 880 mg/dL 以上。反过来，FCS 患者会出现心脏代谢和其他并发症，如糖尿病、肝脂肪变性、腹痛甚至认知问题。据Arrowhead 称，目前美国还没有可以充分控制 FCS 的治疗方法。 ApoC3 蛋白在肝细胞中自然产生，是富含甘油三酯脂蛋白的成分。plozasiran通过沉默ApoC3基因的表达，从根本上促进甘油三酯的清除。 Arrowhead 正在利用 III 期 PALISADE 试验的数据支持其应用。2024 年 11 月的一份读数表明，25 毫克plozasiran可使甘油三酯水平降低约 80%。在至少一半的接受治疗的患者中，甘油三酯水平保持在 500 mg/dl 以下。Plozasiran 治疗还降低了胆固醇水平。 05 Ascendis：TransCon CNP儿童罕见骨生长障碍的新希望最终决定日： 2025年11月30日核心看点： TransCon CNP（navepegritide）能否获批用于治疗软骨发育不全（一种导致侏儒症的罕见遗传病）。该药通过持续补充C型利钠肽，来对抗致病基因对骨骼生长的抑制，从而可以帮助减轻软骨发育不全的症状和并发症的负担。一项随机、双盲和安慰剂对照的II期研究，招募了42名接受6微克、20微克或50微克药物的患者。结果显示，与安慰剂相比，接受TransCon CNP治疗的患者在 52 周时其增长改善就超过基线增长。此外，年化生长速度显着改善，其他方面也有获益，例如稳定的生活质量和更好的身体机能。 06 Cytokinetics：aficamten心肌病市场向BMS发起挑战最终决定日： 2025年12月26日核心看点：能否获批用于梗阻性肥厚型心肌病（oHCM），直接挑战BMS的同类药物Camzyos。 Aficamten 阻断在心脏收缩中发挥作用的心脏肌球蛋白，解决 oHCM 的关键症状。8 月在2025 年欧洲心脏病学会大会上公布的 III 期MAPLE-HCM 研究的数据表明，与美托洛尔（一种用作该疾病标准治疗的 β 受体阻滞剂）相比，运动能力显着提高。被分析师评价为“潜在同类最佳”。 Cytokinetics 于 2024年底申请了 aficamten 的批准，当时 FDA 提供了 2025 年 9 月 26 日的初始目标批准日期。然而，今年 5 月，监管机构将其审查时间延长了三个月，以审查公司提交补充风险控制方案。如果获得批准，aficamten 将与BMS 的 Camzyos 竞争，Camzyos 也是一种心脏肌球蛋白抑制剂，于 2022 年获得 oHCM 批准。该制药公司正在对这种药物进行非阻塞性心脏病的测试，但今年 4 月的一份结果令人失望：Camzyos 在运动能力结果方面无法显著优于安慰剂，也没有带来更好的身体机能。结语第四季度的FDA，注定不会平静。从癌症到罕见病，从基因疗法到小分子药物，每一项决定都承载着无数患者的希望，也牵动着整个生物医药行业的变革。期待这些创新疗法能够早日为患者带来福音。参考文献： https://www.biospace.com/fda/6-fda-decisions-to-watch-for-in-q4 立即扫码加入药事纵横交流群

临床3期免疫疗法申请上市细胞疗法临床2期

2025-10-23

·个人图书馆

梗阻解除率100%！肥心病迎“中国方案”

*仅供医学专业人士阅读参考阜外团队带你读懂HCM诊疗百年变革与国产新药破茧之路。整理：Moon审核专家：许连军、吴雪怡教授2025年欧洲心脏病学会（ESC）年会的余热尚未褪去，一场聚焦肥厚型心肌病（HCM）领域的“学术盛宴”已悄然开启。9月21日，医学界心血管频道联合中国医学科学院阜外医院打造的ESC会后专场直播顺利举行，心内科权威专家康连鸣教授领衔主持，许连军教授、吴雪怡教授先后分享，从HCM的诊疗演进到国产创新药的临床突破，为线上同仁带来了一场兼具国际视野与本土价值的学术分享。本文将整理会议精华内容，以飨读者。一、从基因破译到分层管理：HCM精准诊疗体系的建立与演进 “HCM是心血管领域少有的从分子生物学到临床治疗均实现前沿突破的疾病。”许连军教授在开场中指出，人类对HCM的认知沿“表型识别-病因破译-机制阐明”的路径逐步深入。其中，基因技术的发展成为推动认知跨越的关键节点。1990年MYH7与1995年MYBPC3基因的相继发现，明确HCM是肌小节相关蛋白编码基因变异导致的遗传性疾病。这推动了指南定义的核心修订——从“不明原因的左心室肥厚”升级为“肌小节基因变异所致的心肌肥厚”，HCM诊断准确性得到显著提高。在机制层面，许教授以“肌丝失衡”解释HCM发病本质：健康心肌中40%-50%肌球蛋白处于“超松弛状态”，而HCM患者仅15%-20%处该状态，过多肌球蛋白处于激活状态，导致横桥形成增加，最终引发心肌肥厚、舒张功能障碍及能量代谢异常等改变。这种对病因与发病机制的深度解码，为临床治疗提供了精准靶向的科学依据，目前，HCM已建立起“分层管理、多策并举”的诊疗体系，在直播中，许教授详细拆解了这一诊疗框架。（一）基础诊疗：诊断与风险评估是治疗基础。临床诊断需综合症状与影像学检查，并建议辅以基因检测。目前已发现27个致病基因，MYH7和MYBPC3分别占15%-30%，但仍有25%-30%患者未明确病因。鉴别诊断亦需排除法布雷病、心肌淀粉样变等继发因素。此外，风险评估应动态进行，每年重新评估猝死、心功能、心律失常及梗阻风险，基因结果也建议每2-3年重新解读。（二）药物治疗：从基石用药到靶向突破药物治疗是所有患者的基础选择。β受体阻滞剂作为基石药物，适用于多数患者；不耐受者可换用非二氢吡啶类钙通道阻滞剂。而对于药物应答不佳的梗阻性患者，靶向药物的问世带来了革命性变化。许连军教授指出：“玛伐凯泰的上市，标志着HCM进入分子靶向治疗时代。”这种选择性肌球蛋白抑制剂通过降低肌球蛋白ATP酶活性，减少横桥形成，既能改善流出道梗阻，又能优化能量代谢与舒张功能。另一种候选药Aficamten虽未在国内上市，但其较短的半衰期和更少的药物相互作用，为临床调药提供了更多可能。目前多个国际与国内指南均已明确推荐该类药物。此外，其它在研药物也聚焦于新机制，如心肌代谢调节剂、钙稳态调节剂、血管紧张素受体抑制剂如缬沙坦，及SGLT2抑制剂如恩格列净等，部分已进入临床研究阶段。（三）非药物治疗：手术与介入的精准适配对药物难治患者，减容治疗仍至关重要。改良Morrow手术作为“金标准”，效果明确但操作复杂，仅于少数中心开展。心脏不停跳小切口切除术等微创技术则为外科提供了新选择。介入治疗如酒精消融（PTSMA）、LIWEN术及PESA术也逐步应用，其中PESA术凭借三维超声引导可精准避开传导系统，安全性较高。值得注意的是，基因治疗为HCM带来了“根治性”可能，多项技术如基因置换、编辑和RNA靶向等正从科研走向临床。如基于AAV9载体的基因替代疗法TN-201已在动物实验中验证可提升蛋白表达并延缓疾病进展。随着医学认知的深化与治疗策略的规范化，HCM年死亡率已从6%显著降至0.5%，十年生存率超过95%，患者预后获得根本性改善。许连军教授总结指出，新靶点药物与基因治疗不断涌现，加之国内新型肌球蛋白抑制剂的研发推进，未来将为患者提供更多希望。二、中国力量：国产新药HS1893的临床突破“今年ESC大会上，我们带着国产1.1类创新药HS1893的研究数据登台，收获了国际同行的高度关注。”吴雪怡教授的分享，将直播焦点引向本土创新成果。作为我国自主研发的新型肌球蛋白抑制剂，HS1893与已上市靶向药作用机制相似，能够可逆、特异性抑制心肌肌球蛋白ATP酶活性，其前期动物实验已证实安全性与有效性。为评估其人体应用效果，研究者开展了一项多中心、随机、双盲、安慰剂对照的Ⅰ期临床试验。研究严格设定入选标准：年龄18~85岁、体重指数（BMI）＜35kg/m²，符合HCM诊断标准（左室流出道静息压差≥50mmHg或静息压差≥30mmHg且激发后≥50mmHg，且射血分数≥60%）。患者按3:1比例分组，分别接受药物或安慰剂治疗，连续14天每日两次口服给药，停药后随访至第26天。在60mg bid剂量组纳入的8例患者中，结果显示（图1）：安全性良好，不良事件均为轻度，无严重事件或死亡；左室射血分数平均下降9.1%，最低至55%，停药后可恢复；药代动力学显示血药浓度第8天达稳态，达峰时间约4小时，优于同类进口药物；药效方面，治疗5天使静息流出道压差降低91%，激发后压差降87.4%，生物标志物如肌钙蛋白和氨基末端脑钠肽前体（NT-proBNP）也显著下降。图1吴雪怡教授特别指出：“最令人鼓舞的是100%的治疗响应率，所有患者均实现了流出道梗阻解除。”这一结果为后续Ⅱ、Ⅲ期临床研究奠定了坚实基础。三、专家圆桌：共议HCM诊疗未来在讨论环节，专家强调个体化治疗的重要性。许连军教授介绍，阜外医院早年以改良Morrow手术为主要治疗方式，尤其适用于室间隔极厚、梗阻严重的患者。近年来，靶向药物的应用改变了临床策略，部分患者用药后室间隔厚度显著减小，使“药物替代手术”成为可能。但她同时提醒，需关注肌球蛋白抑制剂可能引发的房颤等风险，应结合患者基础状况谨慎评估。在介入治疗方面，PESA术因安全性高、可重复性强，更适合流出道局限梗阻且室壁不厚的患者，而酒精消融仍是老年或无法耐受外科手术患者的重要选择。谈及HS1893的研发历程，吴雪怡教授分享了研究者的真实心境：“作为1.1类国产新药，首次用于患者时既忐忑又充满使命感。从严格筛选患者、协调多部门精准把控检查时间，到及时处理个别患者的射血分数波动，每一步都凝聚着团队的谨慎与坚持。当看到患者梗阻解除、症状改善时，所有付出都值得了。”最后，康连鸣教授总结指出，HCM诊疗进展是心血管精准医学发展的缩影。从基因机制的阐明到靶向药物的研发，从外科巨创到内科微创，每一次突破都汇聚了科研与临床的共同努力。国产创新药HS1893的亮相，为全球患者提供了“中国方案”，但“万里长征只是迈出了第一步”，未来仍需持续深耕机制探索、新药研发和个体化治疗。专家简介

诊断试剂抗体药物偶联物

2025-10-23

·北京医学感染与传染研究

新英格兰医学杂志 393卷1-16期（2025年10月23日更新）

N Engl J Med[Jour] AND 393[volume] AND 1[issue] 新英格兰医学杂志 393卷1期 https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg PERSPECTIVE（观点） 1 The Corporatization of U.S. Health Care: Defining Health Care “Corporatization” 美国医疗保健的企业化：界定医疗保健“企业化” E.C. Fuse Brown N Engl J Med; July 3, 2025; 393(1)：1-3 2 Self-Neglect in Older People — A Clinical, Social, and Ethical Dilemma 老年人自我忽视——临床、社会和伦理困境 K. Lees Haggerty and D.B. Reuben N Engl J Med; July 3, 2025; 393(1)：4-6 3 Biologic Drugs and Medicare Price Negotiation 生物制剂与医保价格谈判 T.J. Hwang , N.L. Keating , and S.B. Dusetzina N Engl J Med; July 3, 2025; 393(1)：6-9 4 The Autopsy Report 尸检报告 K. Klara N Engl J Med; July 3, 2025; 393(1)：9-11 ORIGINAL ARTICLES（论著） 5 Structured Exercise after Adjuvant Chemotherapy for Colon Cancer 结肠癌辅助化疗后的结构化运动 K.S. Courneya and Others N Engl J Med; July 3, 2025; 393(1)：13-25 6 Tirzepatide as Compared with Semaglutide for the Treatment of Obesity 与司美格鲁肽相比，替西帕肽治疗肥胖症的效果 L.J. Aronne and Others N Engl J Med; July 3, 2025; 393(1)：26-36 7 Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer 局部晚期头颈癌的新型辅助和辅助帕博利珠单抗治疗 R. Uppaluri and Others N Engl J Med; July 3, 2025; 393(1)：37-50 8 Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk 奥贝胆酸在心血管高危患者中的安全性和有效性 S.J. Nicholls and Others N Engl J Med; July 3, 2025; 393(1)：51-61 REVIEW ARTICLE（综述） 9 Forensic Pathology 法医病理学 R.D. Folkerth , B.A. Sampson , and J.K. Graham N Engl J Med; July 3, 2025; 393(1)：62-71 IMAGES IN CLINICAL MEDICINE（临床医学影像） 10 Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis 抗中性粒细胞胞浆抗体相关性血管炎导致的弥漫性肺泡出血 I.S. Lee N Engl J Med; July 3, 2025; 393(1)：72 11 Frostbite Injury from Inhaled Nitrous Oxide Use 吸入一氧化二氮导致的冻伤损伤 M. Patrizio and M. Hayden N Engl J Med; July 3, 2025; 393(1)：e1 CLINICAL PROBLEM-SOLVING（临床问题解决） 12 Caving In to Pressure 屈服于压力 S.I. Gomez-Villegas and Others N Engl J Med; July 3, 2025; 393(1)：73-79 EDITORIALS（社论） 13 The Corporatization of U.S. Health Care — A New Perspective Series 美国医疗保健的企业化——一个新的观点与视角系列 D. Malina and Others N Engl J Med; July 3, 2025; 393(1)：81-82 14 Extending Cancer Survival with Exercise — Time for Oncology to Act 通过运动延长癌症患者生存期——肿瘤学该行动了 M.L. Irwin N Engl J Med; July 3, 2025; 393(1)：82-84 15 Semaglutide and Tirzepatide to Treat Obesity 司美格鲁肽和替西帕肽治疗肥胖症 F.L. Greenway N Engl J Med; July 3, 2025; 393(1)：84-85 16 Harnessing Immunotherapy in Curative-Intent Treatment of Head and Neck Cancer 在头颈癌根治性治疗中运用免疫疗法 A.J. Rosenberg and E.E. Vokes N Engl J Med; July 3, 2025; 393(1)：85-87 SOUNDING BOARD（议事堂） 17 From the National Academy of Medicine: Climate Change and Human Health — A Research Agenda for Action 来自美国国家医学院的观点：气候变化与人类健康——行动研究议程 V.J. Dzau and Others N Engl J Med; July 3, 2025; 393(1)：88-92 CORRESPONDENCE（读者来信） 18 Lifesaving Diagnosis through Prenatal Genomic Sequencing 通过产前基因组测序作出挽救生命的诊断 N Engl J Med; July 3, 2025; 393(1)：93-95 19 Intensive Blood-Pressure Control in Patients with Type 2 Diabetes 2型糖尿病患者强化血压控制 N Engl J Med; July 3, 2025; 393(1)：95-98 20 Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections 血流感染患者抗生素治疗7天与14天的对比 N Engl J Med; July 3, 2025; 393(1)：98-101 21 Dapagliflozin in Patients Undergoing TAVI 接受经导管主动脉瓣植入术患者使用达格列净的情况 N Engl J Med; July 3, 2025; 393(1)：101-103 22 Further Comments on Risdiplam for Prenatal Therapy of Spinal Muscular Atrophy 关于利司扑兰用于脊髓性肌萎缩症产前治疗的进一步评论 N Engl J Med; July 3, 2025; 393(1)：103-104 N Engl J Med[Jour] AND 393[volume] AND 2[issue] 新英格兰医学杂志 393卷2期 https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg PERSPECTIVE（观点） 1 Who Will Care for America? Immigration Policy and the Coming Health Workforce Crisis 谁来关照美国？移民政策与即将到来的医疗劳动力危机 P.M.G. Santos , R. Jagsi , and C.I.A. Oronce N Engl J Med; July 10, 2025; 393(2)：105-107 2 Exclusion of Elective Care from Hospital Financial Assistance Policies — Arresting a Troubling Development 医院财务援助政策中排除择期护理——遏制令人不安的发展态势 M.A. Hall and J. Garber N Engl J Med; July 10, 2025; 393(2)：107-110 3 Libraries Burned, a Life Lived 图书馆被焚，人生如旅 T. Vijayan N Engl J Med; July 10, 2025; 393(2)：110-111 ORIGINAL ARTICLES（论著） 4 As-Needed Albuterol–Budesonide in Mild Asthma 按需使用沙丁胺醇-布地奈德治疗轻度哮喘 C. LaForce and Others N Engl J Med; July 10, 2025; 393(2)：113-124 5 Global Effect of Cardiovascular Risk Factors on Lifetime Estimates 心血管危险因素对终生风险的全球影响 The Global Cardiovascular Risk Consortium N Engl J Med; July 10, 2025; 393(2)：125-138 6 Intravenous Tenecteplase before Thrombectomy in Stroke 卒中血栓切除术前静脉注射替奈普酶 Z. Qiu and Others N Engl J Med; July 10, 2025; 393(2)：139-150 7 Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer Inavolisib治疗PIK3CA突变型晚期乳腺癌的总生存期 K.L. Jhaveri and Others N Engl J Med; July 10, 2025; 393(2)：151-161 REVIEW ARTICLE（综述） 8 Juvenile Idiopathic Arthritis 幼年特发性关节炎 C.I. Sandborg , G.S. Schulert , and Y. Kimura N Engl J Med; July 10, 2025; 393(2)：162-174 IMAGES IN CLINICAL MEDICINE（临床医学影像） 9 Whipple’s Disease with Endocarditis 伴有心内膜炎的惠普尔病 P. Ackermann and M.A. Borger N Engl J Med; July 10, 2025; 393(2)：175 10 Incarcerated Femoral Hernia 嵌顿性股疝 P. Rana and H. Jivani N Engl J Med; July 10, 2025; 393(2)：e2 CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录） 11 Case 19-2025: A 69-Year-Old Man with Headache and Ataxia 病例19-2025：一名69岁男性，头痛且共济失调 A. Venkatesan and Others N Engl J Med; July 10, 2025; 393(2)：176-184 EDITORIALS（社论） 12 Your Combination Asthma Inhaler — Don’t Leave Home without It! 你的联合哮喘吸入器——出门别忘了带！ J.M. Drazen N Engl J Med; July 10, 2025; 393(2)：186-187 13 Estimates of Cardiovascular Risks and Benefits — When Knowing Is Not Enough 心血管风险和获益的评估——光知晓并不够 G.A. Mensah N Engl J Med; July 10, 2025; 393(2)：187-189 14 Thrombolysis before Thrombectomy in Stroke — A Bridge Not Fallen 卒中血栓切除术前溶栓治疗——一座未坍塌的桥梁 T.W. Leung N Engl J Med; July 10, 2025; 393(2)：189-191 SOUNDING BOARD（议事堂） 15 From the National Academy of Medicine: Transforming Health Care — Shared Commitments for a Learning Health System 来自美国国家医学院的观点：转变医疗保健模式——构建学习型医疗系统的共同承诺 J.L. Madara and Others N Engl J Med; July 10, 2025; 393(2)：192-197 CORRESPONDENCE（通信） 16 Expansion of tetM-Carrying Neisseria gonorrhoeae in the United States, 2018–2024 2018-2024年美国携带tetM的淋病奈瑟菌的扩散情况 N Engl J Med; July 10, 2025; 393(2)：198-200 17 Atrial Appendage Closure after Ablation for Atrial Fibrillation 心房颤动消融术后左心耳封堵 N Engl J Med; July 10, 2025; 393(2)：200-203 18 Tumor-Infiltrating Clonal Hematopoiesis 肿瘤浸润性克隆性造血 N Engl J Med; July 10, 2025; 393(2)：203-205 19 Wealth and Mortality in the United States and Europe 美国和欧洲的财富与死亡率 N Engl J Med; July 10, 2025; 393(2)：205-207 20 Addressing Alcohol Use 应对酒精使用问题 N Engl J Med; July 10, 2025; 393(2)：207-208 N Engl J Med[Jour] AND 393[volume] AND 3[issue] 新英格兰医学杂志 393卷3期 https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg PERSPECTIVE（观点） 1 The Role of Public Health Agencies in Creating Vaccine Policy 公共卫生机构在制定疫苗政策中的作用 P. Marks N Engl J Med; July 17, 2025; 393(3):209-211 2 New Mammography Tools — The Need for Clinically Meaningful Assessment Standards 新的乳腺钼靶工具——需要有临床意义的评估标准 B. Hyams , K. Kerlikowske , and R.F. Redberg N Engl J Med; July 17, 2025; 393(3):211-213 3 The Second Life of Jacqui B. Jacqui B.的第二人生。 M. Earnest and P. Khazanie N Engl J Med; July 17, 2025; 393(3):214-215 ORIGINAL ARTICLES（论著） 4 Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer 杜伐鲁单抗在胃和胃食管结癌围手术期的应用 Y.Y. Janjigian and Others N Engl J Med; July 17, 2025; 393(3):217-230 5 First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate 强的松或甲氨蝶呤治疗肺结节病的一线治疗 V. Kahlmann and Others N Engl J Med; July 17, 2025; 393(3):231-242 6 Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin 环磷酰胺和环孢素预防移植物抗宿主病 D.J. Curtis and Others N Engl J Med; July 17, 2025; 393(3):243-254 7 Multidose Ondansetron after Emergency Visits in Children with Gastroenteritis 小儿肠胃炎急诊后多剂量昂丹司琼的疗效 S.B. Freedman and Others N Engl J Med; July 17, 2025; 393(3):255-266 8 Brief Report: Rapid Recovery of Donor Hearts for Transplantation after Circulatory Death 简要报告：供体心脏在循环性死亡后快速恢复 A.M. Williams and Others N Engl J Med; July 17, 2025; 393(3):267-274 9 Brief Report: On-Table Reanimation of a Pediatric Heart from Donation after Circulatory Death 简要报告：一名循环死亡后捐赠的儿童心脏在手术台上复活 J.A. Kucera , D.M. Overbey , and J.W. Turek N Engl J Med; July 17, 2025; 393(3):275-280 REVIEW ARTICLE(综述) 10 The Spectrum of Fragile X Disorders 脆性X染色体紊乱谱系 R.J. Hagerman and P.J. Hagerman N Engl J Med; July 17, 2025; 393(3):281-288 IMAGES IN CLINICAL MEDICINE（临床医学影像学） 11 Acrometastases Acrometastases H. O’Rourke and M. Iddawela N Engl J Med; July 17, 2025; 393(3):289 12 Microcysts in Lithium-Induced Nephropathy 锂诱发肾病中的微囊 C.-H. Liao and K.-L. Liu N Engl J Med; July 17, 2025; 393(3):e3 CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马赛诸塞州总医院病例记录） 13 Case 20-2025: An 86-Year-Old Woman with Neck Swelling and Dysphagia 病例20-2025:86岁女性，颈部肿胀和吞咽困难 M.L. Russell and Others N Engl J Med; July 17, 2025; 393(3):290-300 EDITORIALS（社论） 14 New Perioperative Strategy in Gastric Cancer 胃癌围手术期新策略 K. Shitara N Engl J Med; July 17, 2025; 393(3):302-303 15 Methotrexate as Initial Therapy for Symptomatic Pulmonary Sarcoidosis? 甲氨蝶呤作为症状性肺结节病的初始治疗？ R.P. Baughman and E.E. Lower N Engl J Med; July 17, 2025; 393(3):303-305 CORRESPONDENCE（通信） 16 Monoclonal Anti–Platelet Factor 4 Antibodies in Recurrent Pregnancy Loss 单克隆抗血小板因子4抗体在复发性妊娠丢失中的作用 N Engl J Med; July 17, 2025; 393(3):306-309 17 Apixaban for Cancer-Associated Venous Thromboembolism 阿哌沙班治疗癌症相关静脉血栓栓塞 N Engl J Med; July 17, 2025; 393(3):309-312 N Engl J Med[Jour] AND 393[volume] AND 4[issue] 新英格兰医学杂志 393卷4期 https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg PERSPECTIVE(观点) 1 Brain Death in Pregnancy — Abortion, Advance-Directive, or End-of-Life Law? 妊娠期脑死亡——人工流产、预先指示还是临终法律问题？ K. Watson N Engl J Med; July 24, 2025; 393(4):313-315 2 The Faulty Logic behind the Supreme Court’s Failure to Protect Trans Minors 最高法院未能保护跨性别未成年人的逻辑谬误 S. Skinner-Thompson N Engl J Med; July 24, 2025; 393(4):316-318 3 The Promise of Real-World Data for Research — What Are We Missing? 现实世界数据研究的前景——我们错过了什么？ A.B. Abbasi , L.H. Curtis , and R.M. Califf N Engl J Med; July 24, 2025; 393(4):318-321 4 Avocado and Salt 鳄梨和盐 G. Yi N Engl J Med; July 24, 2025; 393(4):321-323 ORIGINAL ARTICLES(论著) 5 Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy 未接受胰岛素治疗的2型糖尿病患者的每周固定剂量艾塞那肽胰岛素 J. Rosenstock and Others N Engl J Med; July 24, 2025; 393(4):325-335 6 Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer 德曲妥珠单抗或雷莫芦单抗联合紫杉醇治疗胃癌 K. Shitara and Others N Engl J Med; July 24, 2025; 393(4):336-348 7 Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy 塔拉他单抗在小细胞肺癌铂基化疗后的疗效 G. Mountzios and Others N Engl J Med; July 24, 2025; 393(4):349-361 8 Ivermectin to Control Malaria — A Cluster-Randomized Trial 伊维菌素控制疟疾-一项集群随机试验 C. Chaccour and Others N Engl J Med; July 24, 2025; 393(4):362-375 REVIEW ARTICLE(综述) 9 Medical Education: Competency-Based Medical Education at the Front Lines of Patient Care 医学教育：位于患者护理第一线的基于能力的医学教育 D. Cooper and E.S. Holmboe N Engl J Med; July 24, 2025; 393(4):376-388 IMAGES IN CLINICAL MEDICINE(临床医学影像) 10 Löfgren’s Syndrome 洛夫格伦综合征 M. Hassan N Engl J Med; July 24, 2025; 393(4):389 11 Hydroxychloroquine Retinal Toxicity 羟氯喹视网膜毒性 A. Donnelly and N. Horgan N Engl J Med; July 24, 2025; 393(4):e4 INTERACTIVE MEDICAL CASE(互动式医疗案例) 12 A Case of Crackles 一例啰音病例 J.I. Hsu and Others N Engl J Med; July 24, 2025; 393(4):e5 CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL(马赛诸塞州总医院病例记录） 13 Case 21-2025: A 75-Year-Old Man with Cough, Dyspnea, and Hypoxemia 病例21-2025:75岁男性，咳嗽、呼吸困难伴低氧血症 A.M. Anandaiah and Others N Engl J Med; July 24, 2025; 393(4):390-399 EDITORIALS(社论) 14 Weekly Insulins and Therapeutic Burden in Type 2 Diabetes 每周胰岛素与2型糖尿病的治疗负担 J.R. Ingelfinger and C.J. Rosen N Engl J Med; July 24, 2025; 393(4):401-402 15 Ivermectin against Malaria — Good News in Bad Times 伊维菌素抗疟疾——艰难时期的好消息 R.W. Steketee N Engl J Med; July 24, 2025; 393(4):402-404 CLINICAL DECISIONS(临床决策) 16 Statin Therapy for Children 儿童他汀类药物治疗 H.K. Marwah, I.K. Luirink , and M. Mietus-Snyder N Engl J Med; July 24, 2025; 393(4):405-407 CORRESPONDENCE(通信) 17 Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis 奥比妥珠单抗治疗活动性狼疮性肾炎的疗效和安全性 N Engl J Med; July 24, 2025; 393(4):408-410 18 Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a) Lepodisiran -一种靶向脂蛋白(A)的长效干扰性小RNA N Engl J Med; July 24, 2025; 393(4):411-412 19 BCG Revaccination to Prevent Tuberculosis 卡介苗复种预防结核病 N Engl J Med; July 24, 2025; 393(4):412-413 20 Evolving Epidemiology of Mpox in Africa in 2024 2024年非洲猴痘流行病学演变 N Engl J Med; July 24, 2025; 393(4):414 21 Enteral Nutrition in Hospitalized Adults 住院成人肠内营养 N Engl J Med; July 24, 2025; 393(4):415-416 N Engl J Med[Jour] AND 393[volume] AND 5[issue] 新英格兰医学杂志 393卷5期 https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg PERSPECTIVE(观点) 1 Revised Recommendations for Covid-19 Vaccines — U.S. Vaccination Policy under Threat Covid-19疫苗修订建议——美国疫苗接种政策受到威胁 J.L. Schwartz N Engl J Med; July 31, 2025; 393(5):417-419 2 Public Policies, Social Narratives, and Population Health 公共政策、社会叙事与人口健康 A.S. Venkataramani , P.S. Tamber , and A. Iton N Engl J Med; July 31, 2025; 393(5):419-421 3 Into the Valley of the Sick 进入病痛的之谷 S. Wesloh N Engl J Med; July 31, 2025; 393(5):421-423 4 Interactive Perspective: Human Papillomavirus and Cancer 互动视角：人类乳头瘤病毒与癌症 J.R. Barzilay and Others N Engl J Med; July 31, 2025; 393(5):e6 ORIGINAL ARTICLES(论著) 5 Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma 可测量的残留疾病–指导新诊断的骨髓瘤治疗 A. Perrot and Others N Engl J Med; July 31, 2025; 393(5):425-437 6 Mitochondrial Donation and Preimplantation Genetic Testing for mtDNA Disease 线粒体捐献和植入前mtDNA疾病基因检测 L.A. Hyslop and Others N Engl J Med; July 31, 2025; 393(5):438-449 7 A Randomized Trial of Acute Normovolemic Hemodilution in Cardiac Surgery 心脏手术中急性等容血稀释的随机试验 F. Monaco and Others N Engl J Med; July 31, 2025; 393(5):450-460 8 Brief Report: Mitochondrial Donation in a Reproductive Care Pathway for mtDNA Disease 简要报告：线粒体捐赠在mtDNA疾病的生殖保健途径 R. McFarland and Others N Engl J Med; July 31, 2025; 393(5):461-468 9 Brief Report: Resolution of Squamous-Cell Carcinoma by Restoring T-Cell Receptor Signaling 简要报告：通过恢复t细胞受体信号传导来解决鳞状细胞癌 P. Ye and Others N Engl J Med; July 31, 2025; 393(5):469-478 REVIEW ARTICLE(综述文章) 10 Motor Vehicle Crash Prevention 预防机动车辆碰撞 S.G. Klauer and Z.R. Doerzaph N Engl J Med; July 31, 2025; 393(5):479-486 IMAGES IN CLINICAL MEDICINE(临床医学影像) 11 Spontaneous Intracranial Hypotension 自发性颅内低血压 S.B. Owais and Y. Kianirad N Engl J Med; July 31, 2025; 393(5):487 12 Spiderweb-like Vessels in Retinopathy of Prematurity 早产儿视网膜病变中的蜘蛛网状血管 X. Zhao and G. Zhang N Engl J Med; July 31, 2025; 393(5):e7 CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL(马赛诸塞州总医院病例记录） 13 Case 22-2025: A 19-Year-Old Woman with Seizurelike Activity and Odd Behaviors 案例22-2025：一名19岁女性出现癫痫样活动和怪异行为 J.A. Restrepo and Others N Engl J Med; July 31, 2025; 393(5):488-496 EDITORIALS(社论) 14 Opening the Door to Tailored Treatment in Newly Diagnosed Multiple Myeloma 开启新诊断多发性骨髓瘤个性化治疗的大门 P.G. Richardson , N.C. Munshi , and D.L. Longo N Engl J Med; July 31, 2025; 393(5):498-500 15 Reducing the Risks of Mitochondrial Disease in Children 降低儿童线粒体疾病的风险 R. Lovell-Badge N Engl J Med; July 31, 2025; 393(5):500-503 16 Science behind the Study: Advances in Preventing Transmission of Mitochondrial DNA Diseases 研究背后的科学：预防线粒体DNA疾病传播的进展 J. Steffann N Engl J Med; July 31, 2025; 393(5):503-507 MEDICINE AND SOCIETY(医学与社会) 17 Reform and Remedy for Imprecision and Inequity — Ending the Race-Based Evaluation of Occupational Pulmonary Impairment 改革与修正——终结基于种族的职业性肺功能障碍评估 R. Khazanchi and Others N Engl J Med; July 31, 2025; 393(5):508-514 CORRESPONDENCE(通信) 18 Phase 2a Study of Baxdrostat in Primary Aldosteronism 巴司他治疗原发性醛固酮增多症的2a期研究 N Engl J Med; July 31, 2025; 393(5):515-518 19 Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation 脉冲场或低温球囊消融治疗阵发性心房颤动 N Engl J Med; July 31, 2025; 393(5):518-520 N Engl J Med[Jour] AND 393[volume] AND 6[issue] 新英格兰医学杂志 393卷6期 https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg PERSPECTIVE(观点) 1 The Corporatization of U.S. Health Care: A Gilded Age for Patients? The Broken Promises of Profit-Driven Medicine 美国医疗保健公司化：病人的镀金时代？利润驱动的医药破碎的承诺 N. Tomes N Engl J Med;August 7,2025;393(6):521-524 2 Lead Contamination in Milwaukee Schools — The Latest Episode in an Ongoing Toxic Pandemic 密尔沃基学校的铅污染——正在进行的毒性大流行的最新事件 M.S. Kanarek N Engl J Med;August 7,2025;393(6):524-526 3 Training Health Communicators — The Need for a New Approach 培训健康传播者——需要一种新的方法 K. Panthagani and Others N Engl J Med;August 7,2025;393(6):526-529 4 ER and Me 急诊室和我 E. Rourke N Engl J Med;August 7,2025;393(6):529-531 ORIGINAL ARTICLES(论著) 5 Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes 芬尼酮联合恩格列净治疗慢性肾病和2型糖尿病 R. Agarwal and Others N Engl J Med;August 7,2025;393(6):533-543 6 Ciprofloxacin versus Aminoglycoside–Ciprofloxacin for Bubonic Plague 环丙沙星与氨基糖苷-环丙沙星治疗黑死病 R.V. Randremanana and Others N Engl J Med;August 7,2025;393(6):544-555 7 Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer Vepdegestrant：一种用于晚期乳腺癌的PROTAC雌激素受体降解剂 M. Campone and Others N Engl J Med;August 7,2025;393(6):556-568 8 First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer 一线用药卡米兹斯特兰治疗新发ESR1突变的晚期乳腺癌 F.-C. Bidard and Others N Engl J Med;August 7,2025;393(6):569-580 REVIEW ARTICLE(综述) 9 Testosterone Treatment in Middle-Aged and Older Men with Hypogonadism 中老年低促性腺激素性腺功能减退症患者的睾酮治疗 S. Bhasin and P.J. Snyder N Engl J Med;August 7,2025;393(6):581-591 IMAGES IN CLINICAL MEDICINE(临床医学影像) 10 E-Cigarette– or Vaping-Associated Lung Injury 电子烟–或吸电子烟–相关肺损伤 M.Z. Roslly and S.A. Syed Rozhan N Engl J Med;August 7,2025;393(6):592 11 Crusted Scabies 陈年的疥疮 Y.-J. Sun and H. Gong N Engl J Med;August 7,2025;393(6):e8 CLINICAL PROBLEM-SOLVING(临床问题解决) 12 Gasping for Strength 喘息求生 D. Zarhin , H. Kolb , and A. Gadoth N Engl J Med;August 7,2025;393(6):593-599 EDITORIALS(社论) 13 Combination Therapy for Chronic Kidney Disease and Type 2 Diabetes — A Promising Prelude 慢性肾病和2型糖尿病的联合治疗——充满希望的前奏 C. Zoccali and F. Mallamaci N Engl J Med;August 7,2025;393(6):601-602 14 Chipping Away at an Old Foe 逐步击破旧敌 P. Mead N Engl J Med;August 7,2025;393(6):603-604 15 Science behind the Study: Degradation of the Estrogen Receptor in Breast Cancer 研究背后的科学：乳腺癌中雌激素受体的降解 D.P. McDonnell N Engl J Med;August 7,2025;393(6):604-608 MEDICINE AND SOCIETY(医学与社会) 16 Restoring the Infant Mortality Rate as a Measure of Societal Health and Well-Being 恢复将婴儿死亡率作为衡量社会健康和福祉的一项指标 E.A. Harrison , U. Ndulue , and B.O. Ojikutu N Engl J Med;August 7,2025;393(6):609-614 CORRESPONDENCE(通信) 17 Xenon — Propelling Climbers to the Summits of the World’s Highest Mountains? 氙气—推动登山者登顶世界最高的山脉？ N Engl J Med;August 7,2025;393(6):615-616 18 Daratumumab for High-Risk Smoldering Multiple Myeloma 达雷妥尤单抗用于高危沉默型多发性骨髓瘤 N Engl J Med;August 7,2025;393(6):616-617 19 A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes 2型糖尿病患者自动胰岛素输送的随机试验 N Engl J Med;August 7,2025;393(6):617-619 20 Enhanced CAR T-Cell Therapy for Relapsed Lymphoma 增强型CAR T细胞疗法治疗复发性淋巴瘤 N Engl J Med;August 7,2025;393(6):619-620 21 Malaria 疟疾 N Engl J Med;August 7,2025;393(6):620-621 22 Neonatal Fc Receptor — Biology and Therapeutics 新生儿Fc受体——生物学与治疗 N Engl J Med;August 7,2025;393(6):621-623 NEngl J Med[Jour] AND 393[volume] AND 7[issue] 新英格兰医学杂志 393卷7期 https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg PERSPECTIVE(观点) 1 Dismantling Public Health Infrastructure, Endangering American Lives 拆除公共卫生基础设施危及美国人的生命 T.R. Frieden N Engl J Med;August 14,2025;393(7):625-627 2 Progress Lost — The Unraveling of Medicaid and the Affordable Care Act 停滞不前——医疗补助和《平价医疗法案》的瓦解 J. Oberlander N Engl J Med;August 14,2025;393(7):628-629 3 The Resurgence of Private Law in American Health Care 美国医疗保健私法的复兴 C. Robertson and W.N. Epstein N Engl J Med;August 14,2025;393(7):630-631 4 The Serendipitous Dance between Life and Death 生与死之间的偶然之舞 A. Zorigtbaatar N Engl J Med;August 14,2025;393(7):632-633 ORIGINAL ARTICLES(论著) 5 Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity Cagrilintide和Semaglutide联合应用于超重或肥胖的成人 W.T. Garvey and Others N Engl J Med;August 14,2025;393(7):635-647 6 Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes Cagrilintide–Semaglutide在超重或肥胖和2型糖尿病成人中的应用 M.J. Davies and Others N Engl J Med;August 14,2025;393(7):648-659 7 A Crossover Trial of Hospital-Wide Lactated Ringer’s Solution versus Normal Saline 医院范围内的乳酸林格氏溶液与生理盐水的交叉试验 L. McIntyre and Others N Engl J Med;August 14,2025;393(7):660-670 8 Risdiplam in Presymptomatic Spinal Muscular Atrophy Risdiplam治疗亚临床脊髓性肌萎缩症 R.S. Finkel and Others N Engl J Med;August 14,2025;393(7):671-682 REVIEW ARTICLE(综述) 9 Metabolic Dysfunction–Associated Steatotic Liver Disease 代谢功能障碍相关脂肪性肝病 G. Targher , L. Valenti , and C.D. Byrne N Engl J Med;August 14,2025;393(7):683-698 IMAGES IN CLINICAL MEDICINE(临床医学影像) 10 Snowman Sign in Pituitary Macroadenoma 垂体巨腺瘤的雪人征 Y. Zhou and W. Weng N Engl J Med;August 14,2025;393(7):699 11 Ocular Gnathostomiasis 眼型囊尾蚴病 S. Karkhur and A. Gupta N Engl J Med;August 14,2025;393(7):e9 CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL(马萨诸塞州总医院病例记录) 12 Case 23-2025: A 28-Year-Old Woman with Respiratory Failure and Abnormal Chest Imaging 病例23-2025：一例28岁女性，呼吸衰竭伴胸部影像异常 W.J. Janssen and Others N Engl J Med;August 14,2025;393(7):700-710 EDITORIALS(社论) 13 Expanding the Treat-to-Target Toolbox for Obesity and Diabetes Care 扩展肥胖和糖尿病的治疗目标工具箱 C.M. Hales N Engl J Med;August 14,2025;393(7):712-714 14 Science behind the Study: Presymptomatic Treatment of a Genetic Disease with a Small-Molecule Drug 研究背后的科学：小分子药物在遗传性疾病亚临床阶段中的治疗 C.J. Sumner N Engl J Med;August 14,2025;393(7):714-717 15 Reviewers for the Journal, January–June 2025 本杂志2025年1月至6月的审稿人 E.J. Rubin N Engl J Med;August 14,2025;393(7):718 CLINICAL DECISIONS(临床决策) 16 Managing Obesity 肥胖治疗 C.P. Kotanidis , A.M. Lincoff , and S.A. Shikora N Engl J Med;August 14,2025;393(7)::719-721 CORRESPONDENCE(通信) 17 A Naturally Occurring Gain-of-Function Mutation in Factor VIII 因子VIII中自然发生的功能获得突变 N Engl J Med;August 14,2025;393(7):722-724 18 Oral Semaglutide and Cardiovascular Outcomes 口服司美格鲁肽与心血管预后 N Engl J Med;August 14,2025;393(7):724-725 19 Lorundrostat Efficacy and Safety in Uncontrolled Hypertension Lorundrostat在未控制的高血压中的疗效和安全性 N Engl J Med;August 14,2025;393(7):725-727 20 Cancer of Unknown Primary Site 原发部位不明的癌症 N Engl J Med;August 14,2025;393(7):727-728 N Engl J Med[Jour] AND 393[volume] AND 8[issue] 新英格兰医学杂志 393卷 8期 https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg PERSPECTIVE（观点） 1 Preventive Care at the Supreme Court 最高法院谈预防性医疗 N. Bagley N Engl J Med; Aug 21/28, 2025; 393(8)：729-731 2 Regulating Private Equity in Health Care — The Massachusetts Model 医疗保健领域私募股权的监管——马萨诸塞模式 T.C. Tsai , G.S. Meyer , and D. Blumenthal N Engl J Med; Aug 21/28, 2025; 393(8)：731-733 3 Reforming the Prescription Drug User Fee Program 改革处方药用户费用计划 T.J. Ziaks and Others N Engl J Med; Aug 21/28, 2025; 393(8)：734-736 4 The Consultant 顾问视角 T. Adzemovic N Engl J Med; Aug 21/28, 2025; 393(8)：736-739 ORIGINAL ARTICLES（论著） 5 Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer 纳武利尤单抗联合化疗新辅助治疗肺癌的总生存期 P.M. Forde and Others N Engl J Med; Aug 21/28, 2025; 393(8)：741-752 6 Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer 艾琳扎奈坦特用于乳腺癌内分泌治疗引起的血管舒缩症状 F. Cardoso and Others N Engl J Med; Aug 21/28, 2025; 393(8)：753-763 7 Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis 吸入莫格拉斯汀治疗自身免疫性肺泡蛋白沉积症的3期试验 B.C. Trapnell and Others N Engl J Med; Aug 21/28, 2025; 393(8)：764-773 8 Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma 西米普利单抗辅助治疗对比安慰剂用于高危皮肤鳞状细胞癌 D. Rischin and Others N Engl J Med; Aug 21/28, 2025; 393(8)：774-785 REVIEW ARTICLE（综述） 9 Medical Education: Educational Strategies for Clinical Supervision of Artificial Intelligence Use 医学教育：人工智能应用临床监督的教育策略 R.-E.E. Abdulnour , B. Gin , and C.K. Boscardin N Engl J Med; Aug 21/28, 2025; 393(8)：786-797 IMAGES IN CLINICAL MEDICINE（临床医学影像） 10 Paraganglioma in the Organ of Zuckerkandl 颈动脉体旁器官副神经节瘤 R. Cohen and P. Hammill N Engl J Med; Aug 21/28, 2025; 393(8)：798 11 Abdominojugular Reflux Test 腹颈静脉回流试验 S. Bent and G. Dhaliwal N Engl J Med; Aug 21/28, 2025; 393(8)：e10 CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录） 12 Case 24-2025: A 32-Year-Old Woman with Fatigue and Myalgias 2025年第24例病例：一例32岁女性，疲劳伴肌痛 D.G. Kwolek and Others N Engl J Med; Aug 21/28, 2025; 393(8)：799-807 EDITORIALS（社论） 13 Redefining Lung Cancer Therapy — A Long-Awaited Shift in Strategy 重新定义肺癌治疗——期待已久的策略转变 V. Calvo N Engl J Med; Aug 21/28, 2025; 393(8)：809-810 14 Menopausal Symptom Management in Breast Cancer Survivors — A Promising New Option 乳腺癌幸存者的更年期症状管理——一种有前景的新选择 A.H. Partridge N Engl J Med; Aug 21/28, 2025; 393(8)：810-812 15 Science behind the Study: GM-CSF in Autoimmune Pulmonary Alveolar Proteinosis 研究背后的科学：GM-CSF在自身免疫性肺泡蛋白沉积症中的作用 J.F. Seymour N Engl J Med; Aug 21/28, 2025; 393(8)：812-816 SOUNDING BOARD（讨论专区） 16 The Path Forward for Vaccine Policy in the United States 美国疫苗政策的未来之路 H.Y. Chu and Others N Engl J Med; Aug 21/28, 2025; 393(8)：817-822 CORRESPONDENCE（读者来信） 17 Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy 抗BCMA CAR-T细胞治疗后CAR+ T细胞淋巴瘤的靶向治疗 N Engl J Med; Aug 21/28, 2025; 393(8)：823-825 18 Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis 司美格鲁肽治疗代谢相关脂肪性肝炎 N Engl J Med; Aug 21/28, 2025; 393(8)：826-828 19 Omitting Nodal Irradiation after Nodes Clear 淋巴结清除后省略淋巴结放疗 N Engl J Med; Aug 21/28, 2025; 393(8)：828-829 20 AAV Gene Therapy in Severe Hemophilia B 严重血友病B的腺相关病毒（AAV）基因治疗 N Engl J Med; Aug 21/28, 2025; 393(8)：829-830 21 Screening for Prostate Cancer with a Polygenic Risk Score 基于多基因风险评分的前列腺癌筛查 N Engl J Med; Aug 21/28, 2025; 393(8)：831-832 CORRECTION（更正） 22 Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer 恩扎卢胺改善生化复发前列腺癌的预后 N Engl J Med; Aug 21/28, 2025; 393(8)：832 N Engl J Med[Jour] AND 393[volume] AND 9[issue] 新英格兰医学杂志 393卷 9期 https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg PERSPECTIVE（观点） 1 The Corporatization of U.S. Health Care: The Corporatization Deal — Health Care, Investors, and the Profit Priority 美国医疗保健的企业化：企业化交易——医疗保健、投资者与利润优先 A. Chandra and M. Shepard N Engl J Med; Sep 4, 2025; 393(9)：833-835 2 Advancing Physician-Scientist Training in China — Challenges, Gaps, and Future Directions 推进中国医师科学家培养——挑战、差距与未来方向 P. Li and Others N Engl J Med; Sep 4, 2025; 393(9)：836-838 3 The Rise of Drug Innovation in China — Implications for Patient Access in the United States and Globally 中国药物创新的崛起——对美国及全球患者药物可及性的影响 K.N. Vokinger , G. Li , and O.J. Wouters N Engl J Med; Sep 4, 2025; 393(9)：839-841 ORIGINAL ARTICLES（论著） 4 Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial 每月一次的马里德巴特卡弗拉鲁肽治疗肥胖——一项2期试验 A.M. Jastreboff and Others N Engl J Med; Sep 4, 2025; 393(9)：843-857 5 Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes 干细胞衍生的完全分化胰岛用于治疗1型糖尿病 T.W. Reichman and Others N Engl J Med; Sep 4, 2025; 393(9)：858-868 6 One Dose versus Three Doses of Benzathine Penicillin G in Early Syphilis 早期梅毒治疗中苄星青霉素G单次剂量与三次剂量的对比 E.W. Hook III and Others N Engl J Med; Sep 4, 2025; 393(9)：869-878 7 Monoclonal Antibodies in the Pathogenesis of Heparin-Induced Thrombocytopenia 单克隆抗体在肝素诱导的血小板减少症发病机制中的作用 J. Treverton and Others N Engl J Med; Sep 4, 2025; 393(9)：879-886 8 Brief Report: Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression 简短报告：无需免疫抑制的移植同种异体β细胞存活情况 P.-O. Carlsson and Others N Engl J Med; Sep 4, 2025; 393(9)：887-894 REVIEW ARTICLE（综述） 9 Management of Acute Type B Aortic Dissection 急性B型主动脉夹层的管理 F.F. Mussa and P. Kougias N Engl J Med; Sep 4, 2025; 393(9)：895-905 VIDEOS IN CLINICAL MEDICINE（临床医学视频） 10 Ultrasound-Guided Paracentesis 超声引导下腹腔穿刺术 A. Kumar and Others N Engl J Med; Sep 4, 2025; 393(9)：e11 IMAGES IN CLINICAL MEDICINE（临床医学图像） 11 Popeye Sign in Transthyretin Amyloidosis 转甲状腺素蛋白淀粉样变性中的“大力水手”征 S. Kurisu and H. Fujiwara N Engl J Med; Sep 4, 2025; 393(9)：906 12 Radiation Pneumonitis 放射性肺炎 M. Peters and P. Jeene N Engl J Med; Sep 4, 2025; 393(9)：e12 13 Hutchinson’s Sign in Subungual Melanoma In Situ 甲下原位黑色素瘤的Hutchinson征 M. Pasch and J. Tutein Nolthenius N Engl J Med; Sep 4, 2025; 393(9)：e13 CLINICAL PROBLEM-SOLVING（疑难杂症求解探微） 14 A Fruitful Workup 卓有成效的检查过程 N. Jain and Others N Engl J Med; Sep 4, 2025; 393(9)：907-914 EDITORIALS（社论） 15 A Tale of Two Diseases 两种疾病的故事 M.L. Collazo-Clavell N Engl J Med; Sep 4, 2025; 393(9)：916-917 16 Science behind the Study: Replacement of Beta Cells for Type 1 Diabetes 研究背后的科学：1型糖尿病的β细胞替代 K.C. Herold and J.S. Pober N Engl J Med; Sep 4, 2025; 393(9)：917-921 17 Antiquated Tools to Fight an Ancient Foe 用陈旧工具对抗古老敌人 L.A. Barbee and L.H. Bachmann N Engl J Med; Sep 4, 2025; 393(9)：921-923 CORRESPONDENCE（通信） 18 Fulminant Viral Myocarditis Associated with Thogotovirus 与托高托病毒相关的暴发性病毒性心肌炎 N Engl J Med; Sep 4, 2025; 393(9)：924-926 19 Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk 奥比西特拉匹在高心血管风险患者中的安全性与有效性 N Engl J Med; Sep 4, 2025; 393(9)：926-928 20 Porcine Xenotransplantation in End-Stage Kidney Disease 终末期肾病中的猪异种移植 N Engl J Med; Sep 4, 2025; 393(9)：929-931 21 Malnutrition in Older Adults 老年人营养不良 N Engl J Med; Sep 4, 2025; 393(9)：931-933 22 Generative AI in Medicine 医学中的生成式人工智能 N Engl J Med; Sep 4, 2025; 393(9)：933-935 N Engl J Med[Jour] AND 393[volume] AND 10[issue] 新英格兰医学杂志 393卷10期 https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg PERSPECTIVE（观点） 1 Efforts toward Equity: Caring for Patients with Intellectual or Developmental Disabilities —A Curriculum for Residents 迈向公平的努力：照顾有智力或发育障碍的患者——住院医师培训课程 L. Clarke and Others N Engl J Med; Sep 11, 2025; 393(10)：937-939 2 Efforts toward Equity: Diaper Need —An Underrecognized Social Driver of Health 迈向公平的努力：尿布需求——一个未被充分认识的社会健康驱动因素 W. Berry , J. Bonville , and S.D. Blatt N Engl J Med; Sep 11, 2025; 393(10)：939-940 3 Efforts toward Equity: Improving Care Coordination for Indigenous Patients with Cancer 迈向公平的努力：改善对患癌原住民患者的护理协调 A.E. Janitz and Others N Engl J Med; Sep 11, 2025; 393(10)：940-942 4 Health and Medical Research Funding in a Divided America— How to Increase Support 分裂的美国在卫生与医学研究方面的资金投入——如何增加支持 R.J. Blendon , J.M. Benson , and N.B. Le N Engl J Med; Sep 11, 2025; 393(10)：942-945 5 The End of Days 末日终结 I.Thomas N Engl J Med; Sep 11, 2025; 393(10)：945-947 ORIGINAL ARTICLES（论著） 6 Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy Aficamten或美托洛尔单药治疗梗阻性肥厚型心肌病 P. Garcia-Pavia and Others N Engl J Med; Sep 11, 2025; 393(10)：949-960 7 Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy Mavacamten治疗有症状的非梗阻性肥厚型心肌病 M.Y. Desai and Others N Engl J Med; Sep 11, 2025; 393(10)：961-972 8 Multidomain Rehabilitation for Older Patients with Myocardial Infarction 针对老年心肌梗死患者的多领域康复治疗 E. Tonet and Others N Engl J Med; Sep 11, 2025; 393(10)：973-982 9 Marburg Virus Disease in Rwanda, 2024 —Public Health and Clinical Responses 2024年卢旺达的马尔堡病毒病——公共卫生与临床应对措施 S. Nsanzimana and Others N Engl J Med; Sep 11, 2025; 393(10)：983-993 SPECIAL ARTICLE（专题论著） 10 Medications for Opioid Use Disorder in County Jails —Outcomes after Release 县监狱中阿片类药物使用障碍的治疗药物——释放后的结果 P.D. Friedmann and Others N Engl J Med; Sep 11, 2025; 393(10)：994-1003 REVIEW ARTICLE（综述） 11 Hypertrophic Cardiomyopathy 肥厚型心肌病 E. Braunwald N Engl J Med; Sep 11, 2025; 393(10)：1004-1015 IMAGES IN CLINICAL MEDICINE（临床医学影像） 12 Pityriasis Rosea 玫瑰糠疹 E.A. Rallis and C. Verros N Engl J Med; Sep 11, 2025; 393(10)：1016 13 Acute Epididymo-orchitis in IgA Vasculitis IgA血管炎伴急性附睾- 睾丸炎 S. Pariha and C. Hanna N Engl J Med; Sep 11, 2025; 393(10)：e14 14 Ruptured Pulmonary Hydatid Cyst 肺包虫囊肿破裂 Y. Aydin and H. Ogul N Engl J Med; Sep 11, 2025; 393(10)：e15 CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录） 15 Case 25-2025: A 93-Year-Old Woman with Dyspnea and Fatigue 2025年第25例病例：一例93岁女性，呼吸困难伴疲劳 S.V. Arnold and Others N Engl J Med; Sep 11, 2025; 393(10)：1017-1024 EDITORIAL（社论） 16 Expanding the Role of Myosin Inhibition in Hypertrophic Cardiomyopathy — A Tale of Two Conditions 扩大肌球蛋白抑制在肥厚型心肌病中的作用——两种疾病的故事 A.V. Ambardekar N Engl J Med; Sep 11, 2025; 393(10)：1026-1028 MEDICINE AND SOCIETY（医学与社会） 17 The Race-Correction Debates —Progress, Tensions, and Future Directions 种族校正争议——进展、紧张局势和未来方向 D.A. Vyas , L.G. Eisenstein , and D.S. Jones N Engl J Med; Sep 11, 2025; 393(10)：1029-1036 CORRESPONDENCE（读者来信） 18 Long-Term Outcomes of the DanGer Shock Trial DanGer休克试验的长期结果 N Engl J Med; Sep 11, 2025; 393(10)：1037-1038 19 Efruxifermin in Compensated Liver Cirrhosis Caused by MASH Efruxifermin治疗MASH所致的代偿性肝硬化 N Engl J Med; Sep 11, 2025; 393(10)：1038-1039 20 Once-Weekly Mazdutide in Obesity or Overweight 每周一次Mazdutide治疗肥胖或超重 N Engl J Med; Sep 11, 2025; 393(10)：1040 N Engl J Med[Jour] AND 393[volume] AND 11[issue] 新英格兰医学杂志 393卷11期 https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg PERSPECTIVE（观点） 1 Reducing Tobacco Use Worldwide: Integrating Pharmacotherapy into Tobacco Control in Low- and Middle-Income Countries — A Critical Need 全球范围内减少烟草使用：将药物治疗纳入中低收入国家烟草控制——一项迫切需求 N.A. Rigotti , N. Walker , and A.S. Amer Nordin N Engl J Med; Sep 18, 2025; 393(11)：1041-1044 2 Protecting Medicaid Enrollees with Chronic Conditions amid Work Requirements 在工作要求下保护患有慢性病的医疗补助计划（Medicaid）参保人 J.Z. Ayanian N Engl J Med; Sep 18, 2025; 393(11)：1044-1046 3 Ultraprocessed Food on an Ultrafast Track 超加工食品驶入超速发展轨道 D.S. Ludwig N Engl J Med; Sep 18, 2025; 393(11)：1046-1049 4 The Consequences of Silencing the “Voice of CDC” “美国疾控中心之声”被消音的后果 S.A. Rasmussen and Others N Engl J Med; Sep 18, 2025; 393(11)：e16 5 Medicaid on the Chopping Block 医疗补助计划（Medicaid）面临削减 E. Park N Engl J Med; Sep 18, 2025; 393(11)：e17 ORIGINAL ARTICLES（论著） 6 Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer 低剂量阿司匹林用于PI3K突变的局限性结直肠癌 A. Martling and Others N Engl J Med; Sep 18, 2025; 393(11)：1051-1064 7 Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Orforglipron（一种口服小分子GLP-1受体激动剂）用于早期2型糖尿病 J. Rosenstock and Others N Engl J Med; Sep 18, 2025; 393(11)：1065-1076 8 Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity 口服司美格鲁肽25 mg用于超重或肥胖成人 S. Wharton and Others N Engl J Med; Sep 18, 2025; 393(11)：1077-1087 9 Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation 比例辅助通气以缩短机械通气时间 K.J. Bosma and Others N Engl J Med; Sep 18, 2025; 393(11)：1088-1103 REVIEW ARTICLE（综述） 10 Tumor Lysis Syndrome 肿瘤溶解综合征 R.G. Bociek and M. Lunning N Engl J Med; Sep 18, 2025; 393(11)：1104-1116 IMAGES IN CLINICAL MEDICINE（临床医学影像） 11 Subcutaneous Panniculitis-like T-Cell Lymphoma 皮下脂膜炎样T细胞淋巴瘤 S. Okada and M. Nishikubo N Engl J Med; Sep 18, 2025; 393(11)：1117 12 Primary Varicella Infection 原发性水痘感染 O. van Not and D. Rauwerdink N Engl J Med; Sep 18, 2025; 393(11)：e18 CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录） 13 Case 26-2025: An 11-Year-Old Girl with Chest Pain and Bone and Liver Lesions 2025年第26例病例：一例11岁女孩，胸痛伴骨和肝脏病变 L.P. Carter and Others N Engl J Med; Sep 18, 2025; 393(11)：1118-1127 EDITORIALS（社论） 14 Reducing Tobacco Use Worldwide — A New Perspective Series 全球减少烟草使用——新观点系列 N.A. Rigotti and Others N Engl J Med; Sep 18, 2025; 393(11)：1129-1130 15 An Aspirin a Day for Improved Colorectal Cancer Outcomes 每日一片阿司匹林以改善结直肠癌预后 R.M. Goldberg and J.A. Meyerhardt N Engl J Med; Sep 18, 2025; 393(11)：1131-1132 16 Mimicking Complex Receptor Actions with Small(ish) Molecules 用小（型）分子模拟复杂受体作用 D.B. Lowe N Engl J Med; Sep 18, 2025; 393(11)：1133-1134 CORRESPONDENCE（通信） 17 Introduction of Mpox Virus Clade Ib into the Republic of the Congo 猴痘病毒Ib分支传入刚果共和国 N Engl J Med; Sep 18, 2025; 393(11)：1135-1137 18 Perioperative Pembrolizumab in Head and Neck Cancer 围手术期帕博利珠单抗用于头颈癌 N Engl J Med; Sep 18, 2025; 393(11)：1138-1139 19 Ondansetron after ED Visits in Children with Gastroenteritis 儿童胃肠炎急诊就诊后使用昂丹司琼 N Engl J Med; Sep 18, 2025; 393(11)：1139-1141 20 Navigating the Discontinuity Crisis in Medical Education 应对医学教育中的断层危机 N Engl J Med; Sep 18, 2025; 393(11)：1141-1143 21 Fetal Hereditary Thrombotic Thrombocytopenic Purpura 胎儿遗传性血栓性血小板减少性紫癜 N Engl J Med; Sep 18, 2025; 393(11)：1143-1144 N Engl J Med[Jour] AND 393[volume] AND 12[issue] 新英格兰医学杂志 393卷12期 https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg PERSPECTIVE（观点） 1 Structural and Scientific Racism, Science, and Health — Evidence versus Ideology 结构性与科学层面的种族主义、科学与健康——证据与意识形态之争 N. Krieger and M.T. Bassett N Engl J Med; Sep 25, 2025; 393(12)：1145-1148 2 From Health to Wealth — Reframing Global Aid through the Gates Foundation’s Final Chapter 从健康到财富——通过盖茨基金会的终章重新构建全球援助框架 S. Phillips N Engl J Med; Sep 25, 2025; 393(12)：1148-1151 3 Dr. Kolhouse and the Cowboy 科尔豪斯博士与牛仔 M. Earnest N Engl J Med; Sep 25, 2025; 393(12)：1151-1153 ORIGINAL ARTICLES（论著） 4 Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction 地高辛用于射血分数降低的心力衰竭患者 U. Bavendiek and Others N Engl J Med; Sep 25, 2025; 393(12)：1155-1165 5 Apixaban for Extended Treatment of Provoked Venous Thromboembolism 阿哌沙班用于诱因性静脉血栓栓塞症的延长治疗 G. Piazza and Others N Engl J Med; Sep 25, 2025; 393(12)：1166-1176 6 Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia 基于可测量残留病灶指导的慢性淋巴细胞白血病治疗 T. Munir and Others N Engl J Med; Sep 25, 2025; 393(12)：1177-1190 7 Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke 卒中静脉溶栓后早期输注替罗非班 C. Tao and Others N Engl J Med; Sep 25, 2025; 393(12)：1191-1201 REVIEW ARTICLE（综述） 8 Medical Education: Advancing Diagnostic Excellence through Medical Education in Diagnostic Equity 医学教育：通过诊断公平性医学教育推进诊断卓越 D.M. Connor , M.L. Lypson , and C.M. Gonzalez N Engl J Med; Sep 25, 2025; 393(12)：1202-1214 IMAGES IN CLINICAL MEDICINE（临床医学影像） 9 Systemic Mastocytosis 系统性肥大细胞增多症 L. Neves da Silva and A.M. Monteiro N Engl J Med; Sep 25, 2025; 393(12)：1215 10 Doxycycline-Induced Phototoxicity 多西环素诱导的光毒性反应 G. Boyd and C. Cheng N Engl J Med; Sep 25, 2025; 393(12)：e19 INTERACTIVE MEDICAL CASE（互动式医学病例） 11 A Fizzy Fix 气泡疗法 M.A. Crane and Others N Engl J Med; Sep 25, 2025; 393(12)：e20 CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录） 12 Case 27-2025: A 53-Year-Old Man with Embolic Stroke and Left Ventricular Apical Aneurysm 2025年第27例病例：一例53岁男性，患有栓塞性卒中及左心室心尖部动脉瘤 G.C. Stewart and Others N Engl J Med; Sep 25, 2025; 393(12)：1216-1225 EDITORIALS（社论） 13 Digitoxin — A Reminder for Digoxin 地高辛——对洋地黄的提醒 M.A. Pfeffer N Engl J Med; Sep 25, 2025; 393(12)：1227-1228 14 Art within Evidence — Balancing Anticoagulant Duration in VTE Care 证据中的艺术——平衡静脉血栓栓塞症护理中的抗凝时长 N.A. Zakai N Engl J Med; Sep 25, 2025; 393(12)：1229-1230 CLINICAL IMPLICATIONS OF BASIC RESEARCH（基础研究的临床意义） 15 Transformative Research in Cystic Fibrosis 囊性纤维化的变革性研究 E.J. Sorscher N Engl J Med; Sep 25, 2025; 393(12)：1231-1234 16 Surprisingly Complex Assemblies from Low-Complexity Domains 来自低复杂度结构域的惊人复杂组装 T. Mittag N Engl J Med; Sep 25, 2025; 393(12)：1235-1238 CORRESPONDENCE（通信） 17 CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis CD19嵌合抗原受体T细胞疗法治疗多重耐药性溃疡性结肠炎 N Engl J Med; Sep 25, 2025; 393(12)：1239-1241 18 Nonoperative Management of Mismatch Repair–Deficient Tumors 错配修复缺陷肿瘤的非手术治疗 N Engl J Med; Sep 25, 2025; 393(12)：1241-1243 19 Cerebral Embolic Protection during TAVI 经导管主动脉瓣置换术中的脑栓塞保护 N Engl J Med; Sep 25, 2025; 393(12)：1243-1245 20 Global Effect of Cardiovascular Risk Factors on Lifetime Estimates 心血管危险因素对终生估计的全球影响 N Engl J Med; Sep 25, 2025; 393(12)：1245-1248 N Engl J Med[Jour] AND 393[volume] AND 13[issue] 新英格兰医学杂志 393卷13期 https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg PERSPECTIVE（观点） 1 The Corporatization of U.S. Health Care: Insight into Corporate Governance — What Motivates Hospitals and Delivery Systems 美国医疗保健的企业化：企业治理洞察——医院和医疗交付系统的动机何在 S. Lipstein N Engl J Med; Oct 2, 2025; 393(13)：1249-1251 2 The Risks of Pharmaceutical Tariffs for Generic Drug Availability 药品关税对仿制药供应的风险 T.J. Hwang , Q.-D. Trinh , and K.N. Vokinger N Engl J Med; Oct 2, 2025; 393(13)：1252-1253 3 Goals for Opioid Use Disorder Medications — Protection, Remission, and Recovery 阿片类药物使用障碍治疗药物的目标——保护、缓解和康复 A.T. McLellan and N.D. Volkow N Engl J Med; Oct 2, 2025; 393(13)：1253-1255 ORIGINAL ARTICLES（论著） 4 Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis 伴有胃肠炎的严重急性营养不良的静脉补液治疗 K. Maitland and Others N Engl J Med; Oct 2, 2025; 393(13)：1257-1268 5 Medical Imaging and Pediatric and Adolescent Hematologic Cancer Risk 医学影像与儿童和青少年血液系统癌症风险 R. Smith-Bindman and Others N Engl J Med; Oct 2, 2025; 393(13)：1269-1278 6 Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia 使用针对APOC3的奥列扎森治疗中度高甘油三酯血症 B.A. Bergmark and Others N Engl J Med; Oct 2, 2025; 393(13)：1279-1291 7 Clesrovimab for Prevention of RSV Disease in Healthy Infants 克莱斯罗维玛布预防健康婴儿呼吸道合胞病毒疾病 H.J. Zar and Others N Engl J Med; Oct 2, 2025; 393(13)：1292-1303 8 Home-Based Care for Hypertension in Rural South Africa 南非农村地区高血压的家庭护理 M.J. Siedner and Others N Engl J Med; Oct 2, 2025; 393(13)：1304-1314 REVIEW ARTICLE（综述） 9 Monoclonal Gammopathy of Undetermined Significance 意义未定的单克隆丙种球蛋白病 S.V. Rajkumar and S. Kumar N Engl J Med; Oct 2, 2025; 393(13)：1315-1326 IMAGES IN CLINICAL MEDICINE（临床医学图像） 10 Uremic Frost 尿毒症霜 M.A. Wani and Z.H. Shah N Engl J Med; Oct 2, 2025; 393(13)：1327 11 Herpes Simplex Virus Esophagitis 单纯疱疹病毒食管炎 A.Agarwal and A. Agarwal N Engl J Med; Oct 2, 2025; 393(13)：e21 CLINICAL PROBLEM-SOLVING（疑难杂症破解之道） 12 A Shifting Frame 视角转换 A.Terrett and Others N Engl J Med; Oct 2, 2025; 393(13)：1328-1334 EDITORIALS（社论） 13 Data versus Dogma — Safety of Intravenous Rehydration in Severely Malnourished Children 数据与教条之争——严重营养不良儿童静脉补液的安全性 M.J. Peters N Engl J Med; Oct 2, 2025; 393(13)：1336-1337 14 Studying Cancer Risks Associated with Diagnostic Procedures — Interpret Wisely 研究诊断程序相关的癌症风险——明智解读 L.M. Morton N Engl J Med; Oct 2, 2025; 393(13)：1337-1339 CLINICAL DECISIONS（临床决策） 15 Allergy or Assumption of Allergy — When to Test for a Penicillin Allergy 过敏还是假定的过敏——何时进行青霉素过敏测试 H. Marwah , A. Ramsey , and E.M. Macy N Engl J Med; Oct 2, 2025; 393(13)：1340-1342 CORRESPONDENCE（读者来信） 16 Clesrovimab in Infants and Children at Increased Risk for Severe RSV Disease 克莱斯罗维玛布用于有严重呼吸道合胞病毒疾病高风险的婴儿和儿童 N Engl J Med; Oct 2, 2025; 393(13)：1343-1345 17 Nerandomilast in Patients with Pulmonary Fibrosis 奈拉度米拉司特用于肺纤维化患者 N Engl J Med; Oct 2, 2025; 393(13)：1346-1347 18 Trastuzumab Deruxtecan in Gastric Cancer 德曲妥珠单抗用于胃癌 N Engl J Med; Oct 2, 2025; 393(13)：1347-1348 19 Tarlatamab in Small-Cell Lung Cancer 塔拉他玛布用于小细胞肺癌 N Engl J Med; Oct 2, 2025; 393(13)：1348-1349 20 Cyclophosphamide and Cyclosporin for GVHD Prevention 环磷酰胺和环孢素预防移植物抗宿主病 N Engl J Med; Oct 2, 2025; 393(13)：1349-1351 N Engl J Med[Jour] AND 393[volume] AND 14[issue] 新英格兰医学杂志 393卷14期 https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg PERSPECTIVE（观点） 1 Occupational Health and Safety on the Chopping Block — What’s at Stake? 职业健康与安全岌岌可危——有何利害关系？ A.T. Gabrielson and C. Corwin N Engl J Med; Oct 9, 2025; 393(14)：1353-1355 2 Emergency Medicaid at Risk — Preserving State Authority and Access to Care 紧急医疗补助岌岌可危——维护州政府权限与医疗保障可及性 J.A. Budhu and Others N Engl J Med; Oct 9, 2025; 393(14)：1356-1358 3 Pharmaceutical Wholesalers — Under-the-Radar Middlemen? 药品批发商——鲜为人知的中间商？ H. Rooke-Ley and R.E. Sachs N Engl J Med; Oct 9, 2025; 393(14)：1358-1360 4 “You Still Going to Be Doing This?” “你还会坚持下去吗？” E.J. Shapiro N Engl J Med; Oct 9, 2025; 393(14)：1360-1361 ORIGINAL ARTICLES（论著） 5 Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension 巴克斯德罗沙特（Baxdrostat）治疗未控制及难治性高血压的疗效与安全性 J.M. Flack and Others N Engl J Med; Oct 9, 2025; 393(14)：1363-1374 6 Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy 针对伴有多发性神经病的遗传性转甲状腺素蛋白淀粉样变性病的Nexiguran Ziclumeran基因编辑疗法 J.D. Gillmore and Others N Engl J Med; Oct 9, 2025; 393(14)：1375-1386 7 Randomized Trial of Targeted Indoor Spraying to Prevent Aedes-Borne Diseases 靶向室内喷洒预防埃及伊蚊传播疾病的随机试验 N.E. Dean and Others N Engl J Med; Oct 9, 2025; 393(14)：1387-1398 8 Permethrin-Treated Baby Wraps for the Prevention of Malaria 使用氯菊酯处理过的婴儿包裹物预防疟疾 R.M. Boyce and Others N Engl J Med; Oct 9, 2025; 393(14)：1399-1408 REVIEW ARTICLE（综述） 9 Idiopathic Intracranial Hypertension 特发性颅内压增高 J.C. Horton N Engl J Med; Oct 9, 2025; 393(14)：1409-1419 IMAGES IN CLINICAL MEDICINE（临床医学影像） 10 Butterfly Vertebra 蝴蝶椎 S. Ding and X. Pan N Engl J Med; Oct 9, 2025; 393(14)：1420 11 Oral Verruciform Xanthomas 口腔疣状黄瘤 G. Anaya-Saavedra and M. Vázquez-Garduño N Engl J Med; Oct 9, 2025; 393(14)：e22 CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录） 12 Case 28-2025: A 36-Year-Old Man with Abdominal Pain, Fever, and Hypoxemia 2025年第28例病例：一例36岁男性，出现腹痛、发热伴低氧血症 G. Dhaliwal and Others N Engl J Med; Oct 9, 2025; 393(14)：1421-1434 EDITORIAL（社论） 13 Aldosterone Synthase Inhibition for Hypertension 醛固酮合成酶抑制剂治疗高血压 T.J. Guzik and M. Tomaszewski N Engl J Med; Oct 9, 2025; 393(14)：1436-1439 CORRESPONDENCE（读者来信） 14 Specificity of CRISPR-Cas9 Editing in Exagamglogene Autotemcel — Update Exagamglogene Autotemcel中CRISPR-Cas9编码的特异性——更新 N Engl J Med; Oct 9, 2025; 393(14)：1440-1442 15 Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes 每周固定剂量艾氟司他（Efsitora）胰岛素治疗2型糖尿病 N Engl J Med; Oct 9, 2025; 393(14)：1442-1444 16 Diphtheria Outbreak among Migrants in Europe 欧洲移民群体中的白喉疫情 N Engl J Med; Oct 9, 2025; 393(14)：1444-1445 17 Clearance of Squamous-Cell Carcinoma by Restoring T-Cell Receptor Signaling 通过恢复T细胞受体信号传导清除鳞状细胞癌 N Engl J Med; Oct 9, 2025; 393(14)：1446-1447 18 Case 17-2025: A Man with Respiratory Failure and Shock after Kidney Transplantation 2025年第17例病例：一例肾移植后出现呼吸衰竭和休克的患者 N Engl J Med; Oct 9, 2025; 393(14)：1447-1448 N Engl J Med[Jour] AND 393[volume] AND 15[issue] 新英格兰医学杂志 393卷15期 https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg PERSPECTIVE(观点) 1 Reducing Tobacco Use Worldwide: The Contribution of Digital Treatment to Efforts to Reduce Global Tobacco Use 减少全球烟草使用:数字治疗对减少全球烟草使用的贡献 F. Naughton and A. Nadkarni N Engl J Med; October16, 2025; 393(15):1449-1452 2 Advancing Surveillance of Health Care–Associated Infections — Targeting Hospital-Onset Sepsis 推进卫生保健相关感染的监测-针对医院发生的败血症 F. Manzoor , C. Rhee , and M. Klompas N Engl J Med; October16, 2025; 393(15):1452-1454 3 The AI Frontier in Humanitarian Aid — Embracing Possibilities and Addressing Risks 人工智能在人道主义援助中的前沿——拥抱可能性与应对风险 M. Barry , J. Hansen , and G.L. Darmstadt N Engl J Med; October16, 2025; 393(15):1454-1457 4 Proliferation of Prior Authorization in Traditional Medicare — None the WISeR? 传统医疗中预先授权的扩散——更明智了吗？ M. Liu , K.T. Kadakia , and R.K. Wadhera N Engl J Med; October16, 2025; 393(15):1457-1459 5 On Bearing Witness 关于见证 S. Attar N Engl J Med; October16, 2025; 393(15):1459-1461 6 Not Otherwise Specified — Season 3: The Forever Crisis of Primary Care: Alive and Kicking — NOS Episode 3.1 未作特别说明（NOS）——第三季：初级医疗的永恒危机：愈演愈烈 ——NOS第3季第1集 N Engl J Med; October16, 2025; 393(15):e24 ORIGINAL ARTICLES(论著) 7 Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer 宫颈癌中仅行前哨淋巴结活检或联合淋巴结清扫术 H. Tu and Others N Engl J Med; October16, 2025; 393(15):1463-1474 8 A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus Telitacicept治疗系统性红斑狼疮的3期临床试验 R.F. van Vollenhoven and Others N Engl J Med; October16, 2025; 393(15):1475-1485 9 Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency 基因治疗腺苷脱氨酶缺乏症的长期安全性和有效性 C. Booth and Others N Engl J Med; October16, 2025; 393(15):1486-1497 10 Mass Administration of Azithromycin to Infants in Mali to Reduce Mortality 马里婴儿大量使用阿奇霉素以降低死亡率 F.C. Haidara and Others N Engl J Med; October16, 2025; 393(15):1498-1508 CLINICAL PRACTICE(临床实践) 11 Hair Loss in Women 女性脱发 E.A. Olsen N Engl J Med; October16, 2025; 393(15):1509-1520 IMAGES IN CLINICAL MEDICINE(临床医学影像) 12 Pneumococcal Sepsis in a Patient with Asplenia and Hypogammaglobulinemia 脾缺失合并低丙种球蛋白血症患者发生肺炎球菌性败血症 S.J. Starke and I. Miller N Engl J Med; October16, 2025; 393(15):1521 13 Stercoral Colitis 粪石性结肠炎 A. Bajer and E. Levine N Engl J Med; October16, 2025; 393(15): e23 CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL(马萨诸塞州总医院的病例记录) 14 Case 29-2025: A 43-Year-Old Woman with Depression, Suicidal Ideation, and Fever 病例29-2025：一例43岁女性，抑郁、自杀倾向伴发热 M.S. Abers and Others N Engl J Med; October16, 2025; 393(15):1522-1531 EDITORIALS(社论) 15 Risk and Benefit 风险与收益 E.J. Rubin N Engl J Med; October16, 2025; 393(15):1533-1534 16 Sentinel Lymphadenectomy for Early-Stage Cervical Cancer — the New Standard? 早期宫颈癌的前哨淋巴结切除术——新标准？ K. Bixel N Engl J Med; October16, 2025; 393(15):1534-1536 MEDICINE AND SOCIETY(医学与社会) 17 The Primary Care Puzzle: Is a Long-Simmering Crisis Boiling Over? U.S. Primary Care Today 初级医疗之谜：长期酝酿的危机正在爆发？美国初级医疗现状 L. Rosenbaum N Engl J Med; October16, 2025; 393(15):1537-1541 CORRESPONDENCE(通信) 18 In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus 体内CD19 CAR T细胞疗法治疗难治性系统性红斑狼疮 N Engl J Med; October16, 2025; 393(15):1542-1544 19 BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease 顽固性自身免疫性疾病患者的BCMA T细胞接合疗法 N Engl J Med; October16, 2025; 393(15):1544-1547 20 Competency-Based Medical Education at the Front Lines of Patient Care 以能力为本的一线患者护理医学教育 N Engl J Med; October16, 2025; 393(15):1548-1550 21 More about the Phase 2a Study of Baxdrostat in Primary Aldosteronism 更多关于巴司他治疗原发性醛固酮增多症的2a期研究 N Engl J Med; October16, 2025; 393(15):1550-1552 N Engl J Med[Jour] AND 393[volume] AND 16[issue] 新英格兰医学杂志 393卷16期 https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg PERSPECTIVE（观点） 1 Involving Palliative Care to Improve Outcomes in Sickle Cell Disease 纳入姑息治疗以改善镰状细胞病预后 E. Nwogu-Onyemkpa and Others N Engl J Med; Oct 23, 2025; 393(16)：1553-1556 2 Thirty Years of Hydroxyurea for Sickle Cell Anemia — Scientific Progress, Global Health Gaps 羟基脲治疗镰状细胞贫血三十年——科学进展与全球健康差距 E. Costa and Others N Engl J Med; Oct 23, 2025; 393(16)：1556-1559 3 Fetal Personhood and Reproductive Criminalization — Implications for Patients, Clinicians, and Public Health 胎儿人格与生殖犯罪化——对患者、临床医生和公共卫生的影响 T. Riley and A. Hassan N Engl J Med; Oct 23, 2025; 393(16)：1559-1561 4 Living in the Present Tense 活在当下 J.A. Feinstein N Engl J Med; Oct 23, 2025; 393(16)：1561-1563 5 Not Otherwise Specified — Season 3: The Forever Crisis of Primary Care: Can AI Solve Primary Care? — NOS Episode 3.2 未作他类说明——第三季：初级保健的永恒危机：人工智能能否解决初级保健问题？——未作他类说明第3.2集 N Engl J Med; Oct 23, 2025; 393(16)：e25 ORIGINAL ARTICLES（论著） 6 Hypertonic Saline or Carbocisteine in Bronchiectasis 高渗盐水或羧甲司坦治疗支气管扩张症 J.M. Bradley and Others N Engl J Med; Oct 23, 2025; 393(16)：1565-1577 7 Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation 接受口服抗凝治疗的慢性冠状动脉综合征患者使用阿司匹林的情况 G. Lemesle and Others N Engl J Med; Oct 23, 2025; 393(16)：1578-1588 8 Common Diseases in Clinical Cohorts — Not Always What They Seem 临床队列中的常见疾病——并不总是如表面所见 F. Rahimov and Others N Engl J Med; Oct 23, 2025; 393(16)：1589-1598 9 Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis 诊断后第一年内使用索塔生塞普（Sotatercept）治疗肺动脉高压 V.V. McLaughlin and Others N Engl J Med; Oct 23, 2025; 393(16)：1599-1611 10 Association of 2024–2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans 2024-2025年新冠疫苗与美国退伍军人新冠结局的关联 M. Cai , Y. Xie , and Z. Al-Aly N Engl J Med; Oct 23, 2025; 393(16)：1612-1623 REVIEW ARTICLE（综述） 11 Medical Education: Educational Strategies to Prepare Trainees for Clinical Uncertainty 医学教育：为受训者应对临床不确定性做准备的教育策略 J.S. Ilgen and G. Dhaliwal N Engl J Med; Oct 23, 2025; 393(16)：1624-1632 IMAGES IN CLINICAL MEDICINE（临床医学影像） 12 Human East African Trypanosomiasis 人类东非锥虫病 L. Veletzky and S. Winkler N Engl J Med; Oct 23, 2025; 393(16)：1633 13 Thoracic Ectopia Cordis 胸部心脏异位 Z. Duric and H. Gasparovic N Engl J Med; Oct 23, 2025; 393(16)：e26 CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录） 14 Case 30-2025: An 82-Year-Old Woman with Abdominal Distention, Edema, and Pleural Effusion 2025年30号病例：一名82岁女性，出现腹部膨隆、水肿和胸腔积液 Z. Kanjee and Others N Engl J Med; Oct 23, 2025; 393(16)：1634-1644 EDITORIALS（社论） 15 Time to Reconsider Mucoactive Agents for Airway Clearance 是时候重新考虑用于气道廓清的黏液活性药物了 J. Hansen-Flaschen and G. Tino N Engl J Med; Oct 23, 2025; 393(16)：1646-1647 16 A Rare-in-Common Paradigm for Precision Genomic Medicine 精准基因组医学中的“罕见共性”范式 P.N. Robinson N Engl J Med; Oct 23, 2025; 393(16)：1648-1649 CORRESPONDENCE（读者来信） 17 Resurgence of Zoonotic Highly Pathogenic Avian Influenza A(H5N1) Virus in Cambodia 柬埔寨人畜共患高致病性禽流感A(H5N1)病毒卷土重来 N Engl J Med; Oct 23, 2025; 393(16)：1650-1652 18 Perioperative Durvalumab in Gastric Cancer 胃癌围手术期使用度伐利尤单抗 N Engl J Med; Oct 23, 2025; 393(16)：1652-1654 19 Tirzepatide vs. Semaglutide for Obesity Treatment 替西帕肽与司美格鲁肽治疗肥胖症的对比 N Engl J Med; Oct 23, 2025; 393(16)：1654-1656

临床结果临床2期

100 项与艾非凯泰相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
梗阻性肥厚型心肌病	申请上市	中国	Cytokinetics, Inc.	2024-10-15
非梗阻性肥厚型心肌病	临床3期	美国	Cytokinetics, Inc.	2023-08-30
非梗阻性肥厚型心肌病	临床3期	中国	Cytokinetics, Inc.	2023-08-30
非梗阻性肥厚型心肌病	临床3期	日本	Cytokinetics, Inc.	2023-08-30
非梗阻性肥厚型心肌病	临床3期	阿根廷	Cytokinetics, Inc.	2023-08-30
非梗阻性肥厚型心肌病	临床3期	澳大利亚	Cytokinetics, Inc.	2023-08-30
非梗阻性肥厚型心肌病	临床3期	巴西	Cytokinetics, Inc.	2023-08-30
非梗阻性肥厚型心肌病	临床3期	加拿大	Cytokinetics, Inc.	2023-08-30
非梗阻性肥厚型心肌病	临床3期	丹麦	Cytokinetics, Inc.	2023-08-30
非梗阻性肥厚型心肌病	临床3期	法国	Cytokinetics, Inc.	2023-08-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05767346 (MAPLE-HCM, Company_Website) 人工标引	临床3期	梗阻性肥厚型心肌病	-	Aficamten	築觸餘構構廠憲廠蓋窪(夢簾襯艱獵鹽製壓窪窪) = 選獵鹽壓鬱襯衊餘膚選蓋醖衊鹹襯衊願鹹窪製 (鑰膚鬱鏇築襯網蓋範窪 ) 更多	优效	2025-09-29
				Metoprolol	-
NCT04848506 (FOREST-HCM, Company_Website) 人工标引	临床2/3期	非梗阻性肥厚型心肌病	34	Aficamten (post-REDWOOD-HCM Cohort 4)	鑰淵製廠蓋遞廠膚製淵(鹹鬱願鏇鬱襯願鏇膚遞) = 餘淵襯積餘簾餘壓製廠範鹹壓範鹹齋餘簾膚鑰 (顧構鬱遞衊醖襯夢淵願 ) 更多	积极	2025-09-29
NCT05767346 (MAPLE-HCM, Pubmed \| N Engl J Med) 人工标引	临床3期	梗阻性肥厚型心肌病	175	Aficamten	製鹽網糧餘艱鏇餘憲夢(網觸築鹽積積繭網憲獵) = 鹽積繭簾獵積獵窪鬱淵壓選鹽醖壓鑰觸淵顧衊 (製獵膚獵網繭製衊遞範, 0.5 ~ 1.7)	优效	2025-09-11
				Metoprolol	製鹽網糧餘艱鏇餘憲夢(網觸築鹽積積繭網憲獵) = 觸鬱齋網範遞製艱網選壓選鹽醖壓鑰觸淵顧衊 (製獵膚獵網繭製衊遞範, -1.7 ~ -0.8)
NCT04848506 (FOREST-HCM, Pubmed \| JACC Heart Fail)	临床2/3期	梗阻性肥厚型心肌病	213	Aficamten 5 mg	廠膚齋鬱鬱鏇遞糧網鏇(襯膚壓衊顧廠壓齋壓願) = 2 (4.3%) asymptomatic and transient instances of left ventricular ejection fraction <50% (range: 47%-49%), neither resulting in drug discontinuation 繭觸構構糧壓鏇襯鬱膚 (選壓遞鹹鏇壓製糧獵繭 ) 更多	积极	2025-08-01
				Aficamten ≤20 mg
NCT05767346 (MAPLE-HCM, Pubmed \| J Am Coll Cardiol)	临床3期	梗阻性肥厚型心肌病	175	Aficamten 5 to 20 mg	齋鹽蓋齋壓糧鹽範醖膚(襯簾鏇觸簾壓齋構範醖) = 廠窪窪襯積鏇築鏇糧窪壓壓淵遞鑰餘壓遞衊遞 (襯網糧蓋餘窪獵餘願襯 ) 更多	积极	2025-08-01
				Metoprolol 50 to 200 mg	-
NCT05767346 (MAPLE-HCM, GlobeNewswire \| NEWS) 人工标引	临床3期	梗阻性肥厚型心肌病	-	Aficamten	膚遞窪憲鏇網憲鹹繭構(鏇夢壓鑰鬱積齋憲齋淵) = MAPLE-HCM met its primary endpoint, demonstrating a statistically significant improvement in peak oxygen uptake (pVO2) from baseline to Week 24 for aficamten compared to metoprolol. 憲築艱簾夢窪鹽窪艱蓋 (衊繭艱壓襯鹽膚積築夢 ) 达到	积极	2025-05-13
				Metoprolol
NCT05186818 (SEQUOIA-HCM, GlobeNewswire) 人工标引	临床3期	肥大型心肌病	-	Aficamten	衊膚憲衊夢淵壓齋簾顧(襯夢製觸蓋衊網範壓鏇) = 繭鏇鹹網鏇鹹築艱艱蓋醖網壓齋構獵鏇齋膚觸 (蓋範簾淵蓋獵窪網夢遞, 3.1) 更多	积极	2024-11-16
				Placebo	衊膚憲衊夢淵壓齋簾顧(襯夢製觸蓋衊網範壓鏇) = 簾壓窪積鑰餘積顧構鏇醖網壓齋構獵鏇齋膚觸 (蓋範簾淵蓋獵窪網夢遞, 2.7) 更多
NCT05186818 (SEQUOIA-HCM, Pubmed \| J Am Coll Cardiol)	临床3期	梗阻性肥厚型心肌病 N-terminal pro-B-type natriuretic peptide	-	Aficamten	繭鏇憲蓋鏇壓蓋積壓遞(醖範艱膚艱餘廠憲鏇鹹) = 糧鹹鬱膚鑰憲觸膚夢齋積鏇窪夢範憲艱築構糧 (選範衊獵廠獵膚齋選壓 ) 更多	积极	2024-11-01
				Placebo	繭鏇憲蓋鏇壓蓋積壓遞(醖範艱膚艱餘廠憲鏇鹹) = 獵築憲膚膚簾鹽衊製淵積鏇窪夢範憲艱築構糧 (選範衊獵廠獵膚齋選壓 ) 更多
NCT05186818 (SEQUOIA-HCM, Pubmed \| J Am Coll Cardiol)	临床3期	梗阻性肥厚型心肌病 N-terminal pro-B-type natriuretic peptide (NT-proBNP)	282	Aficamten	齋網衊鏇鬱夢艱夢鹹範(願築糧蓋顧觸觸襯夢窪) = 淵網餘鑰遞鹽襯壓齋壓壓簾醖鹽構膚選觸鹹夢 (夢獵淵鬱衊糧選顧製願 ) 更多	积极	2024-11-01
NCT05186818 (SEQUOIA-HCM, Pubmed \| J Am Coll Cardiol)	临床3期	梗阻性肥厚型心肌病	282	Aficamten	遞鏇醖鹽願淵壓製糧淵(構鬱憲獵獵積鬱衊鹽觸) = 窪壓製觸淵鏇製蓋壓網鹹鑰簾遞鏇範積衊製築 (廠糧顧製壓糧築衊衊窪, -25 ~ -6) 更多	积极	2024-11-01